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Chapter 1
General introduction and outline  




Diabetes mellitus is characterized by chronically elevated blood glucose levels 
(hyperglycemia). Diabetes can be classified in several types, with type 1 and 
type 2 diabetes being the most common (and most known) types. Diabetes 
is a major health problem that has reached alarming levels. The estimated 
prevalence of diabetes in Europe in 2019 was 59.3 million people, representing 
8.9% of the adult population, a number that will increase to 68 million in the 
coming 25 years. In 2019, more than 450,000 deaths in adults were attributable 
to diabetes and its complications, representing 8.5% of all-cause mortality (1). 
The estimated prevalence of diabetes in the Netherlands in 2018 was almost 1.2 
million people, with an incidence of 53,600 people per year. Almost 2,700 people 
died because of diabetes mellitus in the past year (2). Chronic hyperglycemia is 
a risk factor for both microvascular, e.g. retinopathy, neuropathy, nephropathy, 
and macrovascular complications, e.g. cardiovascular disease (3). These long 
term complications cause significant human suffering with respect to disease 
burden, loss of quality of life and reduced life expectancy. Hence, the goal of 
diabetes treatment is to prevent long-term complications by aiming for near 
normal glucose levels. 
Compared to other regions in the world, Europe has the highest number of 
children and adolescents with type 1 diabetes (1). Type 1 diabetes is caused by 
islet-specific auto-immunity, eventually causing almost complete β-cell loss in 
the islets of Langerhans in the pancreas, leading to absolute insulin deficiency. 
The auto-immunity results from a complex interplay between environmental 
factors and the microbiome, genome, metabolism and immune systems (4). 
People with (newly onset of) type 1 diabetes classically present with symptoms 
of polydipsia, polyuria and weight loss. Diabetic ketoacidosis is the second 
most common form of presentation for type 1 diabetes. In adults, the onset of 
disease can be more variable. Type 1 diabetes can occur at any age, with the 
majority of cases occurring in adulthood (5). Because of the absolute insulin 
deficiency, people with type 1 diabetes always require insulin replacement 
therapy to control blood glucose levels. In order to mimic human physiology, 
it is usually advised to use insulin according to a basal-bolus regimen, either 
by multiple daily injections (MDI) with a combination of long-acting and short-
acting insulins or by continuous subcutaneous insulin infusion (CSII), containing 
short-acting insulin alone.
Type 2 diabetes is by far the most common type of diabetes in adults (>90%) 
and results from a combination of insulin resistance and relative insulin 




even more so in children and adolescents, because of rising levels of obesity, 
physical inactivity and unhealthy diets (1). Lifestyle interventions are the 
cornerstone of treatment for people with type 2 diabetes. These include dietary 
advice, increasing physical activity levels and weight reduction. However, 
because lifestyle interventions are often not sufficient to achieve widely 
recommended target levels for glucose control, the current guidelines usually 
advocate treatment with metformin and additional oral agents as needed for 
treatment of type 2 diabetes in early disease stages. Since pancreatic beta cell 
function gradually declines, (additional) insulin therapy is usually needed when 
the disease progresses. Most people with type 2 diabetes also require treatment 
for hypertension and hypercholesterolemia and, when smoking, are strongly 
advised to quit this habit, as part of cardiovascular disease risk management. 
Insulin therapy
As stated above, patients with type 1 diabetes and those with type 2 diabetes 
approaching absolute insulin deficiency are dependent on insulin therapy, 
preferably according to basal-bolus regimens to mimic the physiology of 
endogenous insulin release by pancreatic beta cells as closely as possible. 
Insulin therapy can be divided into different types, based on pharmacodynamic 
and pharmacokinetic properties. These include short-, intermediate- and long-
acting insulins and premixed insulins, that consist of a combination of short- 
and long-acting insulin. The basal component of basal-bolus insulin therapy 
is used to mimic physiological insulin secretion in the absence of food, usually 
provided by long- or intermediate-acting insulin products or by the basal rate 
of an insulin pump. The bolus component of such a regimen is used to mimic 
the secretion of insulin from the pancreas in response to food, usually provided 
by short-acting insulin products, either by (pen) injection or an insulin pump 
(6). In daily clinical practice, however, achieving (near-) normoglycemia 
with therapeutic insulin remains challenging for which hypoglycemia is often 
the principal limiting factor (7), part of which is due to the limitations of 
therapeutic insulin. Exogenously administered insulin differs substantially from 
physiological endogenous insulin secretion in terms of timing, dose and route 
of administration (8). Indeed, exogenous insulin is injected subcutaneously 
rather than in the portal vein, absorption of which into the bloodstream takes 
more time, depending on local blood flow and temperature (9), and results in 
systemic hyperinsulinemia. Also, once exogenous insulin is injected, insulin 
levels cannot be regulated and only gradually decrease, whereas the dose of 
endogenous insulin is proportional to the amount of carbohydrates ingested.
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Frequent monitoring of glucose levels, either by finger pricks or continuously 
by a glucose sensor, is of great importance to achieve optimal insulin therapy. 
The frequency of self-monitoring of blood glucose (SMBG) should be 
individualized for each patient based on the specific insulin regimen. Patients 
taking multiple doses of insulin are strongly advised to check their blood 
glucose levels before (and sometimes after) each meal and before bedtime, 
whereas patients treated with only (once daily) basal insulin may need to only 
check once daily. Optimal insulin therapy requires patients to estimate the 
amount of prandial insulin before each meal according to several factors. These 
factors include the current blood glucose level, target blood glucose level, 
carbohydrate intake, insulin-to-carbohydrate ratio (ICR), insulin sensitivity 
and anticipated physical activity (10). Optimal insulin bolus dosing is hard, but 
can be supported by bolus calculation tools in which calculated individualized 
ICR and insulin sensitivity are already integrated. Use of bolus calculation tools 
have been shown to improve glucose control and quality of life in patients with 
suboptimally controlled diabetes on MDI treatment and patients who recently 
started CSII therapy (10-14). Given the many factors that influence blood 
glucose levels, however, it is almost impossible to perfectly match insulin need 
with insulin administration, resulting in both hyper- and hypoglycemic episodes. 
While episodes of hyperglycemia underly long-term complications but do not 
immediately result in symptoms, episodes of hypoglycemia can increase the 
risk to develop severe, potentially hazardous, hypoglycemia when patients do 
not undertake immediate action. 
Hypoglycemia
The occurrence of hypoglycemia is a fact of life for most people with diabetes 
on insulin therapy, particularly those with type 1 diabetes aiming to optimize 
glucose control. It remains an unpredictable side effect of insulin therapy, 
affecting the physical and emotional wellbeing of patients with diabetes. People 
with diabetes starting insulin therapy should be educated about prevention, 
recognition and treatment of hypoglycemic events. There is an ongoing debate 
about the exact glucose cut-off values that define hypoglycemia and its severity. 
Recently, the International Hypoglycemia Study Group proposed a 3-level 
classification for insulin-induced hypoglycemia. In this classification, a glucose 
level at or below 3.9 mmol/l is termed an alert value, which may or may not 
require immediate treatment. Clinically important hypoglycemia is defined as a 
glucose level <3.0 mmol/L, based in part on its association with cardiovascular 
events and the development of defective glucose counterregulation and of 
impaired awareness of hypoglycemia (IAH), when recurrent (see discussion 




impairment requiring external assistance for recovery (15). Risk factors for 
hypoglycemia in patients with diabetes include intensive treatment with insulin, 
glinides or sulfonylurea, decreased endogenous glucose production following 
alcohol ingestion and increased glucose utilization during exercise (16, 17). 
The frequency of hypoglycemic events is variable between individuals and 
patients not always inform their specialist about hypoglycemia. People with 
type 1 diabetes experience on average 2-3 hypoglycemic events per week, 
whereas people with type 2 diabetes on insulin experience 2-3 hypoglycemic 
events per month (18). On average, people with type 1 diabetes suffer from 
one episode of severe, at least temporarily disabling, hypoglycemia every 
year. Rates of severe hypoglycemia in patient with type 2 diabetes treated with 
insulin are approximately tenfold lower than in patients with type 1 diabetes, 
although the studies on which this estimate is based are relatively small  (19, 20). 
Although most people recover uneventfully from (even recurrent) hypoglycemia, 
these events can cause harm and are occasionally fatal. Indeed, 5-10% of 
deaths among people with type 1 diabetes under the age of 50 have been 
attributed to hypoglycemia, for example hypoglycemia-induced fatal arrhythmia 
(21). Also, severe hypoglycemia is associated with an increased risk of all-
cause mortality and cardiovascular disease, in particular in patients with type 2 
diabetes (21-25). 
Glucose counterregulation
A decrease in blood glucose level normally initiates a cascade of reactions in the 
body, also known as glucose counterregulation (Fig. 1). First, there is a decrease 
in insulin release by the pancreatic β-cells in the islets of Langerhans, leading 
to increased hepatic glucose production and decreased glucose utilization. 
Increased glucagon levels produced by the α-cells in the islets of Langerhans 
further stimulate hepatic gluconeogenesis. When glucose levels drop further, 
catecholamines are released, which additionally stimulate hepatic glucose 
production and limit glucose utilization by adipose tissue and skeletal muscle. 
Cortisol and growth hormone are also involved in the defense against in particular 
prolonged hypoglycemia by decreasing glucose utilization and increasing 
glucose production, but their role in acute counterregulation is limited. When 
glucose levels drop below 3.1 mmol/l autonomic symptoms (e.g., sweating, 
trembling, heart pounding and feeling hungry) are initiated as a warning 
sign for patients to correct low glucose levels by ingestion of carbohydrates. 
Neuroglycopenic symptoms, which reflect brain glucose deprivation, include 
difficulty concentrating, feeling faint, reduced consciousness and eventually 
coma, and occur at glucose levels that are substantially lower (7, 8). 
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In patients with type 1 diabetes and advanced type 2 diabetes, hypoglycemia 
by definition cannot result in decreased insulin secretion by pancreatic β-cells, 
so that the first line defense against hypoglycemia is already lost. This loss 
coincides with a functional defect in the glucagon response to hypoglycemia, 
possibly resulting from impaired intra-islet communication between pancreatic 
β- and α-cells. Both these defects create a risk for iatrogenic hypoglycemia. 
In addition, since antecedent hypoglycemia has been shown to attenuate the 
adrenomedullary response to a subsequent episode, recurrent hypoglycemia 
may lead to defective glucose counterregulation and the absence of symptomatic 
awareness. As a consequence, glycemic thresholds for counterregulatory 
responses to hypoglycemia vary between individuals, but also within individuals, 
depending on the (recent) exposure to hypoglycemic events and/or (chronic) 
hyperglycemia. In people with poorly controlled diabetes these thresholds shift 
to higher plasma glucose concentrations, whereas in people with tight glycemic 
control there is a shift to lower plasma glucose concentrations, due to a usually 
higher burden of hypoglycemia (16). 
Impaired awareness of hypoglycemia 
Some patients with diabetes lose the capacity to timely detect hypoglycemia, 
a clinical condition referred to as impaired awareness of hypoglycemia (IAH). 
IAH is usually the result of a process of habituation to the counterregulation-
suppressive effect of recurrent hypoglycemia (Fig. 2). IAH increases the risk of 
developing severe hypoglycemia by a factor 6 or more (27-29). The incidence of 
IAH has not changed in the last 2-3 decades, despite the introduction of insulin 
analogues and improved insulin delivery systems. IAH has been well described 
in patients with type 1 diabetes, where it has been reported to affect up to one 
third of the adult population (28, 30-35). Little information is known about 
the prevalence of IAH in people with type 2 diabetes, with small-scale studies 
reporting this to vary between 7 and 46% among those using insulin (36-40). 
The exact mechanisms that underly the hypoglycemia-habituating process 
leading up to IAH have not been fully elucidated. Alterations in the brain may 
play a pivotal role in this process, including alterations in cerebral blood flow 
(CBF) and lactate handling. Hypoglycemia has been shown to increase CBF in 
patients with type 1 diabetes and IAH, but not in those with normal awareness 
of hypoglycemia (NAH) or in healthy volunteers (41). The increase in global 
CBF may enhance nutrient supply to the brain, possibly in an attempt to protect 
the brain from hypoglycemia-induced harm, simultaneously suppressing 
symptomatic awareness of hypoglycemia (42). Glucose is the primary energy 



















































non-glucose fuel substrates. These alternative fuel substrates include ketones, 
lactate and amino acids (43). Brain lactate has been shown to decrease in 
response to hypoglycemia in patients with type 1 diabetes and IAH. The fall 
in brain lactate may be a consequence of increased brain lactate oxidation. 
This lactate may be used as alternative fuel source during hypoglycemia, and 
therefore may contribute to impaired awareness of hypoglycemia (44), but 
the exact mechanism of lactate in impaired awareness of hypoglycemia and 
whether there is a link with CBF requires further research.
Treatment strategies for impaired awareness of hypoglycemia
IAH is a functional defect and strict avoidance of hypoglycemic events for 3-4 
weeks can reverse this process (45-47). While it is possible to minimize the 
risk of hypoglycemia and maintain some degree of glycemic control, iatrogenic 
hypoglycemia remains the limiting factor in the management of patients 
with diabetes. Strict avoidance of hypoglycemia often deteriorates glycemic 
control, which increases the risk of development of micro- and macrovascular 
complications. Continuous subcutaneous insulin infusion has been shown to 
reduce severe hypoglycemia in patients with type 1 diabetes when compared 
to multiple daily insulin injections. However, there are no data that show 
improvement of IAH in patients on CSII. Addition of automated bolus calculation 
to CSII have been suggested to reduce the incidence of hypoglycemia and 
consequently improve IAH, but data supporting this notion are lacking.  
Other options to restore awareness of hypoglycemia are structured educational 
programs, for example UK’s Dose Adjustment for Normal Eating (DAFNE), the 
US program Blood Glucose Awareness Training (BGAT) and the Dutch ‘Hypo-
Bewust’ online program. Patients learn how to detect and interpret glucose 
values on the basis of internal cues and knowledge of glucose-modulating 
factors, and to determine when to treat low or high blood glucose levels. After 
following these programs patients had significant fewer severe hypoglycemic 
events, were better at estimating blood glucose levels and had reduced blood 
glucose fluctuations (29, 48-52). However, although awareness of hypoglycemia 
improved in some patients involved in such programs, this was not a universal 
finding. 
A more recent and increasingly available option to achieve better glucose 
control and avoid hypoglycemia at the same time, especially in patients with 
IAH, is the use of continuous glucose monitoring (CGM). CGM devices display 
an estimate of blood glucose levels and trends in glucose changes. Patients 








































































patients with type 1 diabetes and IAH has shown an improvement of time spent 
in normoglycemia, a decrease in time spent in hypoglycemia and a decrease 
in glucose variability. Particularly in people with IAH, use of CGM has been 
associated with about halving the incidence of severe hypoglycemia (53-55). 
However, despite ameliorating the consequences of IAH, use of CGM was not 
associated with an improvement in self-reported awareness of hypoglycemia 
(54, 56-58). 
Previous studies have examined whether pharmacological treatment could 
reverse the process of IAH. Caffeine and theophylline have been shown to 
increase the counterregulatory hormone responses to hypoglycemia and 
improve the perception of hypoglycemia in patients with type 1 diabetes (59, 
60). However, long-term use of theophylline is associated with the development 
of tolerance (61, 62). Administration of other agents like naloxone, diazoxide 
and terbutaline have also shown to improve the counterregulatory hormone 
responses to hypoglycemia or to prevent hypoglycemia in patients with type 1 
diabetes, however, these were only single-dose administrations (63-65). 
Conclusion
In conclusion, iatrogenic hypoglycemia remains the most frequent complication 
of insulin therapy in people with diabetes, feared by patients and relatives and 
a barrier to achieving durable optimal glucose control. This is particularly true 
for the condition of impaired awareness of hypoglycemia, induced by recurrent 
hypoglycemic events. IAH remains an important clinical problem in the 
management of diabetes, in particular because of the considerably increased 
risk of severe hypoglycemia, leading to potential hazardous situations for both 
patients and their environment. Restoring awareness in people with IAH is 
difficult and hard to sustain, especially without running the risk of deterioration 
of glycemic control. Despite improvements in insulin therapy (with insulin 
analogs or CSII), educational programs and increasing use of CGM, studies 
have generally not been able to show that such interventions improve IAH in 
the long-term. There still is an unmet medical need for treatment options to 
prevent hypoglycemia or to reverse the process of IAH in patients with insulin-




Outline of the thesis 
As outlined above, better understanding of the underlying mechanism and 
prevalence of IAH and effective therapeutic interventions to restore or maintain 
hypoglycemic awareness are urgently needed. The overall aim of this thesis is to 
provide further insight into the pathophysiology of IAH, examine the prevalence 
of IAH in type 2 diabetes and investigate treatment options that reduce the risk 
of hypoglycemia without deteriorating overall glucose control and improve 
awareness of hypoglycemia in patients with IAH.  
Several studies have been performed to unravel the underlying mechanism of 
development of IAH. 
Previous studies have shown that hypoglycemia leads to a redistribution 
of cerebral blood flow (CBF) towards the thalamus in patients with normal 
awareness of hypoglycemia and healthy controls, suggesting that the thalamus 
is involved in the coordination of the sympathetic response to hypoglycemia. 
In patients with IAH, global CBF is increased during hypoglycemia, but there is 
no redistribution towards the thalamus. Furthermore, hypoglycemia has been 
shown to reduce brain lactate levels in patients with IAH, suggesting oxidation 
of lactate as alternative fuel when glucose levels are low. Brain lactate has been 
suggested to function as a regulator of brain processes, but whether lactate is 
involved in changes in global CBF is not known. In chapter 2, we investigate 
the effect of lactate administration during hypoglycemia on CBF responses in 
patients with type 1 diabetes and normal awareness of hypoglycemia, using 
arterial spin labeling (ASL) MRI to measure CBF.
The prevalence of IAH in patients with type 1 diabetes has been well described, 
but substantially less information is available regarding the prevalence of IAH 
in type 2 diabetes. Studies that have been performed have a small sample 
size and show a high variation in the prevalence of IAH. In chapter 3, we use 
the Dutch Diabetes Pearl cohort to examine the prevalence of IAH and severe 
hypoglycemia in people with type 2 diabetes on insulin in the Netherlands. The 
Dutch Diabetes Pearl cohort is an observational cohort study of 6,666 people 
with type 2 diabetes in the Netherlands, about a third of whom are on insulin 
therapy. Data have been collected from patients treated in primary, secondary 
and tertiary care throughout the Netherlands.     
In people with type 1 diabetes on insulin pump therapy, optimal bolus insulin 
dose can be supported by bolus calculation tools. As discussed earlier, it is 
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not clear whether such tools result in less glucose variability and lower risk 
of hypoglycemia in patients with acceptable glucose control who are already 
on insulin pump therapy for several years. In theory, improvement in glucose 
variability may lead to improvement in the awareness of hypoglycemia through 
reduced hypoglycemia burden. In chapter 4, the effects of treatment with a bolus 
calculator versus continuation of standard care without a bolus calculator on 
glucose variability, quality of life and other parameters in an open-label study 
are described in people with type 1 diabetes on CSII. Importantly, improvement 
of already moderate to good glycemic control was not the primary aim of the 
intervention. 
Factors that may be important for both the development and retention of 
IAH are glucose variability and marked hyperglycemia, since overcorrection 
of hyperglycemia creates a risk for hypoglycemia. This leads to a vicious 
cycle of fluctuating glucose levels and recurrent hypoglycemic episodes, 
contributing to IAH. Meticulous avoidance of hypoglycemia for 2-4 weeks can 
reverse the process of IAH. Unfortunately, the often coexistent worsening of 
glycemic control precludes such an approach as a durable treatment option. 
Two relatively new glucose-lowering agents that are increasingly used in the 
treatment of type 2 diabetes, have shown to improve glucose variability in the 
treatment of type 1 diabetes, when added to insulin therapy. First, in chapter 
5, we describe the effect of treatment with the glucagon-like-peptide-1 (GLP-
1) receptor agonist exenatide on awareness of hypoglycemia in patients with 
type 1 diabetes and IAH. By delaying gastric emptying, exenatide may reduce 
postprandial hyperglycemia resulting in decreased glucose variability. 
Similarly, we investigated the effect of another pharmacological intervention 
on awareness of hypoglycemia. Sodium-glucose co transporter 2 (SGLT-
2) inhibitors reduce hyperglycemia and improve glucose control, without 
increasing the risk of hypoglycemia. Studies in patients with type 1 diabetes 
have shown lower HbA1c and less glucose variability with SGLT-2 inhibitors on 
top of insulin treatment. We hypothesize that these effects could translate into 
improved awareness of hypoglycemia. This hypothesis was tested in chapter 6, 
where the effect of treatment with the SGLT-2 inhibitor dapagliflozin on IAH in 
patients with type 1 diabetes is described. 
Finally, the results of the presented studies are summarized and future research 
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Impaired awareness of hypoglycemia, clinically reflected by the inability to 
timely detect hypoglycemia, affects approximately 25% of the people with type 1 
diabetes. Both altered brain lactate handling and increased cerebral blood flow 
(CBF) during hypoglycemia, appear to be involved in the pathogenesis of impaired 
awareness of hypoglycemia. Here we examine the effect of lactate on CBF 
during hypoglycemia. Nine people with type 1 diabetes and normal awareness 
of hypoglycemia underwent two hyperinsulinemic euglycemic-hypoglycemic 
(3.0 mmol/L) glucose clamps in a 3T MR system, once with sodium lactate 
infusion and once with sodium chloride infusion. Global and regional changes 
in cerebral blood flow were determined using pseudo-continuous Arterial Spin 
Labeling (ASL). Lactate infusion suppressed the counterregulatory hormone 
responses to hypoglycemia. Global CBF increased considerably in response to 
intravenous lactate infusion, but did not further increase during hypoglycemia. 
Lactate also blunted the hypoglycemia-induced regional redistribution of CBF 
towards the thalamus. In conclusion, lactate infusion enhances global CBF and 
blunts the thalamic CBF response during hypoglycemia in patients with type 
1 diabetes, mimicking observations of impaired awareness of hypoglycemia. 
These findings suggest that alteration of CBF associated with lactate contributes 
to the development of impaired awareness of hypoglycemia.
Clinical Trial number: NCT03730909
Keywords: cerebral blood flow, clinical trials, diabetes, hypoglycemia, lactate
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Introduction
Hypoglycemia is the most frequent adverse effect of insulin therapy in people 
with type 1 diabetes treated with insulin. If glucose levels drop, a hierarchically 
organized counterregulatory response is initiated, which includes the release of 
counterregulatory hormones and the appearance of hypoglycemic symptoms. 
The ventromedial hypothalamus is thought to be involved in the coordination of 
this sympathetic response to hypoglycemia. Indeed, studies using neuroimaging 
techniques have shown that hypoglycemia results in a redistribution of cerebral 
blood flow (CBF) towards the thalamic areas, as a reflection of increased brain 
activity in patients with type 1 diabetes and normal awareness of hypoglycemia 
(NAH) and in people without diabetes (1-4). 
About one in every four patients with type 1 diabetes is diagnosed with impaired 
awareness of hypoglycemia (IAH), a reduced ability to detect the onset of 
hypoglycemia (5). In patients with IAH, the glucose threshold for the initiation of 
a counterregulatory hormone and symptom response is shifted to lower glucose 
levels, creating a greater risk for severe, potentially hazardous, hypoglycemia 
that requires help from another person for recovery (6). Results of brain 
imaging techniques suggest that the hypoglycemia-induced relative increase in 
thalamic CBF is blunted in patients with IAH, indicating that hypoglycemia fails 
to activate brain areas that coordinate counterregulatory responses (3; 7; 8).
Altered CBF response and altered brain lactate handling have both been 
implicated in the pathogenesis of IAH, and both are probably aimed at 
protecting the brain from harm induced by hypoglycemia.  First, in patients with 
IAH, moderate hypoglycemia increases global CBF (3), a response that usually 
requires deeper hypoglycemia (9; 10). Second, altered lactate handling of the 
brain may be a key process in the development of IAH (11-13). Lactate can be 
oxidized by the brain during hypoglycemia as an alternative fuel source when 
glucose supply is low. Our previous studies have indicated that both the capacity 
to transport lactate across the blood-brain barrier (14) and that of lactate 
oxidation are upregulated in patients with IAH (13). The role of lactate in the 
development of IAH is further supported by the observation that administration 
of lactate diminishes symptomatic and hormonal responses to hypoglycemia 
(15; 16), similarly to the situation seen in IAH. 
It is usually assumed that the excess of lactate in the brain is only used for 
oxidation (17; 18). However, brain lactate may also regulate cerebral perfusion 
to maintain brain glucose metabolism (12). As such, lactate may be involved in 
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the upregulation of global CBF, in order to enhance the supply of nutrients (i.e. 
glucose) to the brain. To test this hypothesis, we examined the effect of lactate 
infusion during hypoglycemia on both regional CBF and global CBF, measured 
by MR techniques, in people with type 1 diabetes and normal awareness of 
hypoglycemia (NAH). 
Materials and Methods
This was a randomized, single-blinded, placebo-controlled cross-over study 
that was performed at the Radboud university medical center in Nijmegen. The 
study was approved by the institutional review board of the Radboud university 
medical center and performed according to the principles of the Declaration of 
Helsinki. All participants gave written informed consent before participation.  
Study population
Patients with type 1 diabetes and NAH were recruited from the outpatient clinic 
of the Radboud university medical center and via advertisements on online 
diabetes platforms. The presence of NAH was assessed by a score of 0 or 1 on 
the Dutch modified translation of the Clarke questionnaire (19). Patients with 
type 1 diabetes were potentially eligible for participation if they were younger 
than 50 years, had a BMI below 30 kg/m2 and HbA1c-levels not exceeding 9.0% 
(75 mmol/mol). Exclusion criteria were the use of medication other than insulin, 
except for oral contraceptives and stable thyroxin supplementation therapy, the 
presence of any other medical condition, micro- or macrovascular complications 
of diabetes and MRI contraindications, such as claustrophobia or the presence 
of metal parts in the body. All subjects were invited for a medical screening prior 
to the investigational days to determine eligibility. 
Study procedure
Participants underwent two hyperinsulinemic euglycemic-hypoglycemic 
glucose clamps, once with concomitant sodium lactate infusion (600 mmol/L) 
and once with saline infusion (500 mL, 0.9%) as placebo. The experimental days 
were separated by at least two weeks. In female subjects, both experiments 
were performed during equal phases of the menstrual cycle. 
On each experimental day, subjects came to the MR research facility in the 
morning in fasting condition, having abstained from alcohol, smoking and 
caffeine containing substances for 24 hours and from strenuous exercise 
for 48 hours. In addition, participants received specific instructions to avoid 
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hypoglycemic incidents the day and night before and the morning of the 
experimental day. Experiments were rescheduled in case of hypoglycemia (i.e., 
glucose levels <3.0 mmol/L) in the 24 hours before the clamp. 
Upon arrival at the MR research facility, the brachial or radial artery of the 
non-dominant arm was cannulated under local anesthesia (Xylocaine 2%) for 
frequent blood sampling. We measured arterial plasma glucose and plasma 
lactate levels (Biosen C-line; EKF Diagnostics) at 5-minute intervals. An 
intravenous catheter was inserted in the antecubital vein of the contralateral 
arm for infusion of insulin (insulin aspart; Novo Nordisk, Bagsvaerd, Denmark), 
glucose 20% (Baxter B.V., Deerfield, IL), and sodium lactate (600 mmol/L; 
Spruyt Hillen, IJsselstein, The Netherlands and prepared by the Department of 
Pharmacy, Radboud university medical center, Nijmegen, The Netherlands) or 
sodium chloride (500 mL; 0.9%) as placebo. 
Subsequently, the participants were placed, in supine position and headfirst, 
in the MR scanner and a hyperinsulinemic euglycemic-hypoglycemic glucose 
clamp was applied. Insulin was infused at a rate of 60 mU·m-2·min-1 and glucose 
20% was infused at a variable rate, aiming for stable plasma glucose levels 
of ~5.0 mmol/L during the euglycemic phase and ~2.8 mmol/L during the 
hypoglycemic phase. After the acquisition of anatomical images, baseline CBF 
data and baseline blood samples (~20 minutes after start of the euglycemic 
clamp), the infusion of sodium lactate, or an equivalent volume of sodium 
chloride, was started. Sodium lactate infusion was started in a dose of 40 
µmol·kg-1·min-1 for 15 minutes, and then continued in a dose of 25 µmol·kg-1·min-1 
for the remainder of the experiment. We aimed for plasma lactate levels of 3.5 
mmol/L. Subsequently, after ~25 minutes, plasma glucose levels were allowed 
to fall to 2.8 mmol/L over approximately 30 minutes and were maintained at that 
level for another 45 minutes.
Prior to entering the MR and at the end of the hypoglycemic phase, symptoms 
of hypoglycemia were assessed on a linear analogue scale with a validated 
questionnaire (19). Patients were asked to score 18 symptoms (autonomic, 
neuroglycopenic, general and dummy) from 0 to 6 (none to most severe). 
Additional blood was sampled for measurement of plasma insulin, pH, glucagon, 
catecholamines, cortisol and growth hormone at several timepoints during the 
euglycemic and hypoglycemic phase, as indicated in figure 1.
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Fig. 1. Schematic overview of the study protocol
MRI protocol
MR measurements were performed at 3T (MAGNETOM Prisma-fit, Siemens, 
Erlangen, Germany) using a body coil for excitation and a 12-channel head 
coil for signal reception. After initial acquisition of localizer images, a T1-
weighted magnetization prepared rapid acquisition with gradient-echo MRI (3D 
MPRAGE) was acquired at 1 mm isotropic resolution. A time of flight angiogram 
was acquired to detect the brain-feeding internal carotid and vertebral arteries 
for accurate positioning of the 17-mm thick labeling slab. The labeling slab was 
positioned perpendicularly to the feeding vessels, about 7-10 cm below the 
anterior commissure - posterior commissure line (AC-PC line).
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The perfusion images were obtained with a pseudo-continuous arterial spin 
labeling (pCASL) MRI research sequence (Fraunhofer Institute for Digital 
Medicine MEVIS, Bremen, Germany). The post-labeling delay was set to 1800 
ms, the labeling duration to 1800 ms and background suppression was applied 
with two hyperbolic secant pulses. A 3D gradient and spin echo (GRASE) 
readout module was used (FOV: 230x173 mm, in-plane resolution: 3.6 mm2 and 
slices of 4.5-mm thickness; partial-Fourier factor of 7/8; turbofactor 11). Echo 
time (TE) was 29.56 ms and repetition time (TR) was 4800 ms. We acquired 
16 pairs of label and control images per time-point, with a scan duration of 
5:22 min. Subsequently, two reference images (proton density, TR: 7000 ms), 
with opposing in-plane phase encoding directions, were acquired without 
spin labeling and without background suppression, for CBF quantification and 
distortion correction. The acquisition of pCASL MRI data and reference images 
was repeated continuously (every ~7 minutes) while the subjects stayed in the 
MR system.
At the end of euglycemic phase and at the beginning of hypoglycemia, a localizer 
and a time of flight angiogram was acquired to visually detect possible subject 
motion. If necessary, the pCASL MRI settings were readjusted accordingly to 
7-10 cm below the AC-PC line.
Analytical methods 
HbA1c was measured by the TOSOH G8 HPLC-analyzer, distributed by Sysmex. 
Plasma insulin was assessed by an in-house radioimmunoassay (20). Plasma 
glucagon was measured by radioimmunoassay (Eurodiagnostica, Malmö, 
Sweden). Plasma adrenaline and noradrenaline were analyzed by high-
performance liquid chromatography combined with fluorometric detection (21). 
Plasma growth hormone and cortisol were determined using a routine analysis 
method with Electrochemiluminescent Immunoassay on a Modular Analytics 
E170 (Roche Diagnostics, GmbH, Mannheim, Germany). pH was measured by 
routine arterial blood gas analysis on the RapidPoint 500 (Siemens Nederland 
B.V., Den Haag, the Netherlands). 
Processing of perfusion images
Images were processed using the FMRIB Software Library (FSL, Version 
6.0.0) (22) and Advanced Normalization Tools (ANTs (2.2.0) (23). Reference 
images, label and control images were motion corrected using linear affine 
registration (MCFLIRT (24)). The motion-corrected label and control images 
were subtracted pairwise, and averaged per timepoint. A susceptibility-induced 
off-resonance field was estimated (22) from the averaged two proton density 
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weighted images (acquired with opposed phase-encoding directions), which 
was used to correct for susceptibility distortions in the proton density as well 
as in perfusion weighted images (25). The CBF maps were registered with the 
subject’s anatomical T1-weighted images, which in turn were registered to the 
MNI152 atlas (MNI152_T1_0.5mm), using linear and non-linear registration 
(antsRegistration). Resampling the CBF maps to the MNI152 atlas allowed a 
voxel-wise comparison over all timepoints. CBF was quantified voxel-wise 
according to the guidelines from Alsop et al. (26). Global CBF values were 
obtained by averaging the CBF values in the gray matter. 
Statistical analysis
Differences between study conditions (lactate vs. placebo) were analyzed with 
paired Student t tests or Wilcoxon signed rank tests if data were not normally 
distributed. The difference in global CBF between periods of euglycemia and 
hypoglycemia within groups, was calculated and expressed relative to baseline 
(i.e., before the start of infusion of lactate or placebo started). Mean regional 
CBF values of caudate, cerebellum, putamen, insula and thalamus, as well as 
frontal, occipital, parietal, and temporal lobes were extracted using region-of-
interests (ROI) from the MNI-maxprob-thr50-2mm atlas (fslmeants). These 
serial data, as well as average plasma glucose levels, counterregulatory hormone 
responses and symptom scores, were compared with two-way repeated 
measure ANOVA with a Bonferroni post-hoc test using IBM SPSS Statistics 25. 
All data are expressed as mean ±standard deviation (SD). Localized changes 
in CBF between the two infusion conditions was assessed with a voxel-wise 
analysis performed together with a parametric general linear model (fsl_glm). 
We generated a design matrix modelling infusion condition (lactate or placebo), 
glycemic state (euglycemia or hypoglycemia), total grey-matter CBF, together 
with factors modelling individual subjects’ intercepts. We tested for glycemic 
effects between infusion conditions. Voxel-wise statistics were corrected at a 
cluster level (easythreshold), and are represented as color-coded thresholded 
z-statistics overlaid on the MNI template (MNI152_T1_0.5mm). A p-value <0.05 
was considered statistically significant. 
Data and Resource Availability
The datasets generated and/or analyzed during the current study are available 
from the corresponding author upon reasonable request. No applicable 
resources were generated or analyzed during the current study.
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Results
A total of 10 patients with type 1 diabetes and NAH were recruited. One patient 
withdrew after the first MRI because of a lack of time to plan the second MRI, two 
were withdrawn, one because of inability to perform arterial cannulation and the 
other because of insufficient quality of CBF maps. These two participants were 
replaced. As a result, 9 participants completed the study and were analyzed. 
Baseline characteristics of these patients are shown in table 1.   
Table 1. Baseline characteristics 
n = 9
Age, years 23.0 ± 3.6
Male gender, n (%) 4 (44.4)
Weight, kg 75.1 ± 13.7
BMI, kg/m² 23.6 ± 2.8
Score on modified Clarke questionnaire 0.0 [0.0, 0.5]
Duration of diabetes, years 7.0 [3.0, 10.5]
Insulin therapy, n (%)
   CSII 6 (66.7)
   MDI 3 (33.3)
Insulin dose, IU/day 47.9 ± 19.2
HbA1c, % (mmol/mol) 7.1 ± 1.0 (54.2 ± 11.1) 
Creatinin, µmol/L 67.1 ± 12.0
Data are presented as number (%), mean±SD or median [IQR]. CSII=continuous subcutaneous 
insulin infusion; MDI= multiple daily injections
Arterial blood glucose levels averaged at 4.7±0.5 mmol/L vs. 4.8±0.4 mmol/L 
during the euglycemic phase (difference -0.09 mmol/L, p=0.66) and 3.0±0.0 
mmol/L vs. 3.0±0.1 mmol/L (difference -0.04 mmol/L, p=0.041) during the 
hypoglycemic phase for lactate and placebo days, respectively (figure 2). 
Baseline plasma lactate levels were similar on both experimental conditions 
(0.7±0.2 mmol/L vs. 0.6±0.2 mmol/L, p=0.54). Plasma lactate levels increased 
within 15 minutes after start of lactate infusion to 3.8±0.5 mmol/L (p<0.001), but 
did not change when sodium chloride was infused (p=0.45 vs. baseline levels) 
(figure 2). Insulin levels were lower on the lactate infusion day at baseline 
(12.2±5.3 vs. 18.1±9.3 mE/L, p=0.049), but increased during the clamp to levels 
similar to those obtained on the placebo day (p=0.51).  Plasma pH increased 
from baseline to the end of hypoglycemia, but the increase was higher during 
lactate than during saline infusion (+0.09±0.03 vs. +0.02±0.01, p=0.001). 
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Glucose infusion rates (GIRs) during hypoglycemia were not significantly 
different between the two clamps (3.7±2.8 vs. 3.5±1.2 mg·kg-1·min-1, lactate vs. 
placebo, p=0.75). 
Fig. 2. (A) arterial glucose levels during lactate infusion (red circles) and placebo infusion 
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Hypoglycemic symptoms and counterregulatory hormone responses
Lactate infusion significantly suppressed adrenaline, noradrenaline, cortisol 
and growth hormone responses to hypoglycemia as compared to placebo 
(Figure 3), while glucagon levels did not differ. The increase in total symptom 
scores in response to hypoglycemia was similar during infusion with lactate 
(from 7.5 to 26.7, p=0.002) and saline (from 7.0 to 26.1, p=0.001). This was also 
true when symptoms were broken down to autonomic and neuroglycopenic 
scores (data not shown).
Global cerebral blood flow
Global CBF did not differ at baseline between the two experimental days. 
Global CBF increased significantly during lactate infusion as compared to saline 
infusion (17.4±10.3% vs. -2.0±6.5%, p=0.001), but global CBF did not change 
further in response to hypoglycemia during either lactate or saline infusion 
(figure 4). 
Regional cerebral blood flow
To assess localized changes in CBF across the whole-brain in association with 
glycemic state and/or infusion type, we leveraged a voxel-wise statistical 
analysis of the CBF maps. Because lactate infusion leads to overall elevated CBF 
levels (Figures 4 and 5) and to determine regional responses, global CBF was 
accounted as a co-variate in our analysis. The increase in CBF in response to 
lactate infusion (Figure 6) was specifically prominent in the posterior cingulate, 
precuneus, and parietal cortex. Significant clusters overlap with the thalamus, 
denoting a decrease in regional CBF under lactate relative to placebo infusion, 
during hypoglycemia. These localized effects were only present when gray-
matter CBF was present as a co-variate, indicating that thalamic and cingulate 
CBF changes are only relative to the global CBF levels. Thus, in addition to 
elevating global CBF, lactate infusion leads to localized CBF redistribution 
specifically within the thalamus and cortical areas, and dependent on the 
glycemic status (hypoglycemia vs. euglycemia).  
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Fig. 3. Counterregulatory hormone levels at baseline (Bsl), during euglycemia (Eu) and during 
hypoglycemia, with lactate infusion (red) and placebo infusion (black), *p<0.05
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Fig. 4. Change in global CBF from baseline during lactate infusion (red circles) and placebo infusion 
(black circles). Bsl=baseline measurement; mean CBF-value of three euglycemic CBF measurements 
without lactate/placebo infusion 
Fig. 5. Quantitative CBF maps averaged over all subjects with T1DM and NAH during euglycemic and 
hypoglycemic state and during infusion of lactate and placebo. CBF values are color coded with the 
Flow[Brain colors] (iso) lookup table and range from 1 to 100 mL/100 g tissue/min
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Fig. 6. Redistribution of CBF in response to hypoglycemia by type of infusion in subjects with T1DM 
and NAH. Z-scores of infusion-induced significant changes in regional CBF are superimposed on the 
axial and sagittal views of the MNI-152 atlas, and indicate a significant increase (red to yellow) or 
decrease (dark to light blue) in regional CBF in lactate relative to placebo infusion. The white underlay 
indicates the thalamus, the black arrows point to the cingulate gyrus.
Discussion
This study shows that lactate infusion significantly increases global CBF, 
although there was no further hypoglycemia-induced change in global CBF in 
patients with type 1 diabetes and NAH. The  regional CBF in the thalamus region 
is blunted during hypoglycemia while CBF in the cingulate, precuneus and 
parietal cortex is enhanced during infusion of lactate. Altogether these findings 
suggest that local alterations of CBF associated with lactate contributes to the 
development of impaired awareness of hypoglycemia.
Previous studies have described an increase in CBF in the thalamic area in 
response to hypoglycemia in patients with type 1 diabetes and NAH and in 
healthy controls, as a reflection of stimulated brain activity that drives the 
autonomic response (1; 2; 27). This increase in thalamic CBF is reduced or 
absent in patients with type 1 diabetes and IAH (3; 7; 8; 28), mirroring the 
reduced autonomic response to hypoglycemia in these people. Here, we used 
a lactate infusion to blunt the autonomic response to hypoglycemia in patients 
with type 1 diabetes, thus mimicking the situation seen in people with IAH. 
Pathogenetic involvement of thalamic blood flow is further supported by the fact 
that lactate infusion resulted in a similar blunting of thalamic activation during 
hypoglycemia. Interestingly, using [15O]water positron emission tomography, 
Arbelaez et al. showed that antecedent hypoglycemia, a different model for IAH, 
enhanced, rather than reduced, CBF response in the dorsal midline thalamus 
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during subsequent hypoglycemia in healthy young adults (1). Whether 
this points towards different pathophysiological mechanisms underlying 
counterregulatory failure or reflect differences in level of detail, neuroimaging 
technique used and/or study population is uncertain. 
We also found an overall increase in global CBF in response to the infusion 
of lactate, which is in accordance with previous studies (29). For example, 
Stewart et al. showed that infusion of a similar dose of lactate as used in the 
present study, resulted in a comparable 20% increase in global CBF under 
otherwise physiological circumstances (30). The lactate-induced increase in 
global CBF might be caused by a shift in the NADH/NAD+ ratio and production 
of reactive oxygen species (ROS), making lactate a regulator of the cerebral 
microcirculation and thus of CBF (31; 32). Previously, we also found an 
increase of 8% in global CBF during hypoglycemia, in patients with type 1 
diabetes and IAH (3). An increase in CBF could be seen as a neuroprotective 
response, as it enhances the supply of glucose and other energy nutrients to 
the brain. However, the consequent maintenance of brain energy metabolism 
may contribute to the suppressed counterregulatory hormone responses and 
impeded hypoglycemic sensing by the brain, as seen in IAH. Similarly, the (twice 
as large) lactate-induced increase in global CBF may have contributed to the 
diminished counterregulatory hormone responses to hypoglycemia, as seen in 
the current study. 
It has been assumed that brain lactate functions primarily as an energy substrate, 
as useful alternative for situations of glucose deprivation. Indeed, we previously 
showed that brain lactate levels fall in response to hypoglycemia in people with 
type 1 diabetes and IAH (13), probably as a result of lactate oxidation. Another 
study also showed increased brain transport and metabolism of non-glucose 
fuels (i.e. acetate and lactate) in people with type 1 diabetes and IAH (33). 
Previous studies suggest that lactate also has a regulatory function with respect 
to brain perfusion (11; 12). This may explain at least in part the increase in CBF 
during hypoglycemia in our study and in turn the consequent greater capacity 
to transport lactate (and other energy substrates) over the blood-brain barrier, 
as we earlier observed in people with IAH (3; 14). Whether the increase in pH 
contributed to the change in CBF cannot be derived from our study. However, 
the change was small and studies in people with traumatic brain injury show that 




Our study has limitations. First, the sample size is rather small although this 
is typical for this type of study. Furthermore, while the hormonal response 
to hypoglycemia was clearly blunted upon lactate infusion, hypoglycemic 
symptoms were not. Participants and personnel were blinded to the type of 
infusion, but participants were informed about the hypoglycemic event. This 
knowledge and the consequent expectations may have influenced the subjective 
reporting of symptoms. The discomfort of lying in the MR scanner may also 
have contributed to the experience of symptoms. Finally, there was a difference 
in electrolyte concentration between the lactate and placebo solution, with 
the sodium lactate solution being hypertonic and the sodium chloride being 
isotonic. Although hypertonic solutions may cause fluid shifts over the blood-
brain barrier, this is unlikely to have had a major impact, since the glucose 
solution used for the clamp in both study-arms is also hypertonic. 
In conclusion, we found that lactate infusion increases global CBF and reduces 
the thalamic CBF response during hypoglycemia in patients with type 1 diabetes 
and NAH, which mimics previous findings in patients with IAH. These results 
strengthen the suggestion that alteration of CBF associated with lactate 
contributes to the development of impaired awareness of hypoglycemia.
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Objective: People with type 2 diabetes on insulin are at risk for hypoglycemia. 
Recurrent hypoglycemia can cause impaired awareness of hypoglycemia 
(IAH), and increase the risk for severe hypoglycemia. The aim of this study was 
to assess the prevalence and determinants of self-reported IAH and severe 
hypoglycemia in a Dutch nationwide cohort of people with insulin-treated type 
2 diabetes.
Research design and methods: Observational study of The Dutch Diabetes 
Pearl, a cohort of people with type 2 diabetes treated in primary, secondary 
and tertiary diabetes care centers. The presence of IAH  and the occurrence of 
severe hypoglycemia in the past year, defined as an event requiring external 
help to recover, were assessed using the validated Dutch version of the Clarke 
questionnaire. In addition, clinical variables were collected including age, 
diabetes duration, hemoglobin A1c, ethnicity and education.
Results: 2350 people with type 2 diabetes on insulin were included: 59.1% 
men, mean age 61.1±10.4 years, mean diabetes duration 14.8±9.2 years and 
79.5% on basal-bolus therapy. A total of 229 patients (9.7%) were classified as 
having IAH and 742 patients (31.6%) reported severe hypoglycemia. Increased 
odds for IAH were found with complex insulin regimens and lower odds with 
having a partner and body mass index ≥30 kg/m2. Severe hypoglycemia was 
associated with complex insulin regimens, non-Caucasian ethnicity and use of 
psychoactive drugs, and inversely with metformin use.
Conclusions: In this nationwide cohort, almost one out of ten people with type 
2 diabetes on insulin had IAH and >30% had a history of severe hypoglycemia in 
the past year.
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What is already known about this subject?
- Use of insulin therapy in patients with type 2 diabetes creates a risk of 
developing (severe) hypoglycemia
- Recurrent (severe) hypoglycemia may lead to the development of impaired 
awareness of hypoglycemia (IAH)
- The prevalence of IAH in patients with type 1 diabetes is around 25%; however, 
less is known about the prevalence of IAH in people with type 2 diabetes
What are the new findings?
- In this nationwide cohort, the prevalence of IAH in patients with type 2 
diabetes on insulin therapy was almost 10%
- The prevalence of severe hypoglycemia in this cohort was more than 30%
- IAH and severe hypoglycemia occur in patients irrespective of whether they 
are managed in primary care or not
How might these results change the focus of research or clinical 
practice?
- Greater awareness for IAH and severe hypoglycemia in people with type 2 
diabetes on insulin is needed





Insulin-related hypoglycemia is a common adverse effect of insulin therapy. 
Recent data show almost 98 000 visits to the emergency department and 30 
000 hospitalizations in the USA per year due to insulin-related hypoglycemia.1 
Over 75% of these emergency department visits occur in middle-aged or 
elderly people, suggesting that most of these people suffer from type 2 
diabetes.
The reported prevalence of hypoglycemic events in people with type 2 
diabetes on insulin therapy is highly variable and partly determined by the 
duration and intensity of insulin therapy. Previous studies have shown that 
people with type 2 diabetes treated with insulin for <2 years experience on 
average four non-severe episodes per person-year, whereas those treated 
for >5 years experience 10 episodes per person-year.2,3 Similarly, severe 
hypoglycemia, defined as an event requiring external help to recover, rarely 
occurs in the first years after the start of insulin therapy but becomes more 
common during later years.4,5 One report estimated the overall prevalence of 
severe hypoglycemia in type 2 diabetes treated with insulin in secondary care 
at 0.28 episodes per patient per year.6  
Recurrent exposure to hypoglycemia can induce a process of habituation 
leading to impaired awareness of hypoglycemia (IAH). This syndrome increases 
the risk for developing severe hypoglycemia considerably,5,6 yet reflects a 
functional defect that can be reversed by strict avoidance of hypoglycemia.7-9 
IAH has been well described in type 1 diabetes and affects approximately 25% of 
people with type 1 diabetes, a percentage that appears relatively stable across 
different cohorts and over time.10-12 Less information is available concerning 
the prevalence of IAH in type 2 diabetes, with reported prevalence of IAH in 
single-centre surveys varying between 7% and 46% among those treated 
with insulin.5,6,13-15 The aim of this study was to assess the prevalence and 
determinants of IAH and severe hypoglycemia in a large nationwide cohort of 
patients with insulin-treated type 2 diabetes.
Research design & methods 
Study design
The Dutch Diabetes Pearl is an observational cohort study of people with type 2 
diabetes in the Netherlands. The participants are managed in primary care (in 
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the Hoorn area or the region of Maastricht) or in secondary and tertiary care in 
seven of the total eight academic medical centers across the country. Details 
on the design of the Dutch Diabetes Pearl have been published previously.16 
The study was approved by Institutional Review Boards of all the participating 
medical centers. Patients were excluded if they were unable to understand and 
write the Dutch language.  
Study population 
Patients were enrolled in the Dutch Diabetes Pearl cohort between 2009 and 
2015.16 For this analysis, we only included patients with type 2 diabetes who 
were treated with insulin. We excluded patients that did not fill in the Clarke 
questionnaire, including all participants from one center that did not administer 
this questionnaire (figure 1). 
Study procedure 
After signing informed consent, data were collected following standard 
operational procedures. Briefly, we collected the following data in the Diabetes 
Pearl: demographics, physical examinations, laboratory measurements and 
several questionnaires including the validated Dutch version of the Clarke 
questionnaire (see below for details).16 
Study outcomes
The primary outcome of this study was the prevalence of IAH in people with 
type 2 diabetes on insulin therapy. All participants were therefore asked 
to complete the clamp-validated Dutch modified translation of the Clarke 
questionnaire.17,18 This questionnaire consists of a validated translation of the 
original five questions; two questions on symptoms of hypoglycemia, one on 
the ability to recognize hypoglycemia based on symptoms, one on the level of 
blood glucose when experiencing hypoglycemic symptoms, and two questions 
on the occurrence of severe hypoglycemia, one relating to the requirement of 
a third party, one relating to the need for medical assistance, both in the past 
year. Each question was awarded with one or zero points, with three or more 
out of five points indicating IAH. Severe hypoglycemia was defined by a positive 
answer to one of both questions regarding severe hypoglycemia. Missing data 
on the Clarke questionnaire were imputed with 0 (having no symptoms) if 
patients filled in at least one answer. 
Other measurements 
We also assessed a range of demographic and clinical factors including 
age, diabetes duration, hemoglobin A1c (HbA1c), ethnicity, smoking, alcohol 
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consumption, having a partner and level of education, to identify potential risk 
factors, as described below.  
Hospital information systems at all recruitment centers were used to collect 
information on date of birth and gender. Ethnicity was estimated as described 
earlier.19 Education level was self-reported. A high educational level was 
defined as higher professional education or university education. Information 
on alcohol consumption and smoking were obtained by questionnaire; smoking 
was categorized as never, former, and current smoking. Body mass index (BMI) 
was defined as a person’s weight (kilograms) divided by square of height 
(meters). Participants brought all their medication or a list from the pharmacy 
to the hospital so that medication use (eg, beta-blockers and psychoactive 
drugs) could be reported accurately. Drug use was divided into three arbitrary 
categories; no polypharmacy (0-4 drugs), moderate polypharmacy (5-9 
drugs) and pronounced polypharmacy (≥10 drugs). The insulin regimen was 
categorized as basal only if it consisted of a long-acting insulin analogue or 
intermediate-acting insulin (ie, NPH (Neutral Protamine Hagedorn) insulin) 
alone, as pre-mixed if it consisted of pre-mixed insulins, and as basal-bolus 
(complex insulin regimen) if it consisted of a combination of long-acting or 
intermediate-acting insulin with short-acting insulin. The latter two regimens 
were considered ‘complex’ for the logistic regression analysis (see below). 
History of cardiovascular disease was defined as at least one of the following 
events having occurred: acute myocardial infarction, cerebrovascular event, 
transient ischemic attack and peripheral artery disease. Information on prior 
cardiovascular disease was assessed by the Rose questionnaire.20 HbA1c 
was reported according to the International Federation of Clinical Chemistry 
and Laboratory Medicine standard.21 Tight glycemic control was defined as 
HbA1c <7% (53 mmol/mol). All measurements took place in certified on-site 
laboratories.16
Statistical analysis 
Data were analyzed using IBM SPSS statistics V.25. Baseline descriptive 
analyses were expressed as mean±SD, proportion or median (25th and 75th 
percentiles). Student’s independent two-sample t-tests and Pearson’s χ2 tests 
were performed to examine differences between groups. We performed logistic 
regression analyses to examine the association between several demographic 
and clinical variables and IAH and severe hypoglycemia. The regression 
model for IAH and severe hypoglycemia were cumulatively adjusted for age, 
sex, diabetes duration, HbA1c, and for other variables that were significantly 
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associated with the outcome in the crude analysis. A p value of <0.05 was 
considered statistically significant. 
Results
The Diabetes Pearl cohort consists of 7018 individuals.16 After excluding 
participants who were not using insulin (n=4303) did not complete the Clarke 
questionnaire (n=226) or had too many missing data on the questionnaire 
(n=139), we included a total of 2350 patients with type 2 diabetes (figure 1). 
There were 59.1% male participants, mean age was 61.1±10.4 years, mean 
diabetes duration 14.8±9.2 years and mean HbA1c 7.9±1.4% (62.5±14.8 mmol/
mol). Almost 80% were on a complex insulin regimen (online supplementary 
table S1). 
Fig. 1. Flow diagram showing patient selection
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Impaired awareness of hypoglycemia
The distribution of the modified Clarke score was highly skewed (online 
supplementary figure S1), with a total of 229 individuals (9.7%) having a score 
of ≥3 points, classifying them as having IAH. Clinical characteristics of the 
individuals with and without IAH are shown in table 1. There were no significant 
differences in the prevalence of IAH between men and women (10.2 vs 9.1%, 
p=NS) and between patients managed in primary or secondary/tertiary 
care (8.2 vs 10.4%, p=NS). Although glycemic control did not differ between 
individuals with or without IAH, the prevalence of IAH was significantly higher 
among individuals with tight glycemic control as compared with those with 
glycemic control that was less tight (p=0.046) (figure 2, top). The presence of 
IAH was associated with complex insulin regimens, non-Caucasian ethnicity, 
lower BMI and not having a partner, and inversely with the use of sulfonylureas. 
After multivariate adjustment, complex insulin regimens, not having a partner 
and lower BMI were still associated with IAH (table 2). There were no statistical 
differences between the two groups concerning smoking, alcohol consumption, 
diabetes duration, and use of beta-blockers or psychoactive drugs. 
Severe hypoglycemia
Severe hypoglycemia in the past 12 months was reported by 742 patients 
(31.6%), 193 (8.2%) of whom required medical intervention. The prevalence 
of severe hypoglycemia was similar across sex, but significantly higher among 
those with poorer glycemic control (p=0.016) (figure 2, bottom). People with a 
history of severe hypoglycemia were more often non-Caucasian, had a longer 
diabetes duration, had a history of cardiovascular events, used psychoactive 
drugs and reported pronounced polypharmacy (table 1). Furthermore, people 
with severe hypoglycemia were more likely to use complex insulin regimens 
and less likely to use sulfonylureas or metformin, and were more often seen 
in secondary/tertiary care than in primary care centers when compared with 
people without severe hypoglycemia. However, after multivariate adjustment, 
the level of care was no longer associated with severe hypoglycemia and the 
same was true for use of sulfonylureas, pronounced polypharmacy and history 
of cardiovascular disease (table 3).
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Table 1. Clinical characteristics of people (N=2350) with or without IAH and severe hypoglycemia








Sex (male) 142 (62.0) 1248 (58.8) 437 (58.9) 953 (59.3)
Age (years) 59.9 ± 11.0 61.2 ± 10.3 60.8 ± 10.5 61.2 ± 10.3
Clinical care 
   Primary care 55 (24.0) 614 (28.9) 185 (25.1)* 484 (30.2)
   Secondary/tertiary care 173 (75.5) 1497 (70.6) 551 (74.9)* 1119 (69.8)
Diabetes duration (years) 15.5 ± 9.7 14.7 ± 9.1 15.7 ± 9.4* 14.3 ± 9.0
HbA1c (%) (mmol/mol) 7.8 ± 1.4 
(61.4 ± 15.3) 
7.9 ± 1.3 
(62.6 ± 14.7) 
8.0 ± 1.4 
(63.7 ± 15.5)
7.8 ± 1.3 
(62.0 ± 14.4)
Insulin treatment 
   Basal only 25 (10.9) † 453 (21.4) 106 (14.3)* 372 (23.1)
   Pre-mixed 40 (17.5) 339 (16.0) 122 (16.4) 257 (16.0)
   Basal-bolus 163 (71.2) † 1327 (62.6) 513 (69.1)* 977 (60.8)
Use of sulfonylurea’s 12 (5.2) † 240 (11.3) 59 (8.0)* 193 (12.0)
Use of metformin 128 (55.9) 1324 (62.4) 423 (57.0)* 1029 (64.0)
Pronounced polypharmacy 73 (31.9) 632 (29.8) 263 (35.4)* 442 (27.5)
Beta blocker use 86 (37.6) 859 (40.5) 298 (40.2) 647 (40.2)
Psychoactive drug use 52 (22.7) 477 (22.5) 209 (28.2)* 320 (19.9)
Ethnicity (Caucasian) 169 (75.4) † 1714 (81.5) 565 (77.2)* 1318 (82.6)
Partner (yes) 122 (63.2) † 1301 (73.5) 443 (72.0) 980 (72.7)
High educational level (yes) 54 (23.8) 499 (23.6) 159 (21.6) 394 (24.6)
Current smoker (yes) 47 (20.6) 389 (18.4) 145 (19.6) 291 (18.2)
High alcohol consumption 
(≥14 glasses/week) 
15 (6.6) 132 (6.3) 49 (6.7) 98 (6.2)
BMI ≥30 (kg/m2) 112 (49.3) † 1198 (57.3) 410 (55.8) 900 (56.9)
History of cardiovascular 
disease (yes) 
81 (35.4) 645 (30.4) 261 (35.2)* 465 (28.9)
Data are shown as number (%) or mean±SD. History of cardiovascular disease was defined 
as having ≥1 of the following; acute myocardial infarction, cerebrovascular event, transient 
ischemic attack, peripheral artery disease. Pronounced polypharmacy was defined as using 
≥10 drugs. * p <0.05 versus no SH. † p <0.05 versus no IAH. BMI, body mass index; IAH, 
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Fig. 2. Proportion (%) of patients with IAH (top) or severe hypoglycemia (bottom) according to 
glycemic category, 7%=53 mmol/mol, 8%=64 mmol/mol, *= p-value for trend <0.05
Conclusions
In this nationwide cohort of patients with type 2 diabetes treated with insulin, 
we found that the prevalence of IAH was 9.7% and that almost one out of three 
individuals reportedly experienced a severe hypoglycemic event in the preceding 
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year. We observed that people not having a partner, with more complex insulin 
treatment regimens, use of psychoactive drugs, BMI <30 kg/m2 and non-
Caucasian descent were more susceptible for IAH or severe hypoglycemia. 
Interestingly, tight glycemic control was associated with a higher prevalence of 
IAH, but at the same time with a lower risk of severe hypoglycemia. Furthermore, 
the prevalence of severe hypoglycemia was significantly higher in secondary/
tertiary care, but the association between level of care and severe hypoglycemia 
was no longer statistically significant after multivariate adjustment. 
Our data on the prevalence of IAH in people with insulin-treated type 2 diabetes 
are in line with those reported in small studies using either the Gold score6,13 
or the Clarke questionnaire,22 and extend these to a more general population 
of people with type 2 diabetes on insulin, including those from primary care. 
In accordance with previous findings, participants with IAH had somewhat 
tighter and those with severe hypoglycemia had somewhat poorer metabolic 
control.13,23,24 Our data contrast with single-center surveys from Denmark5,14 
and Turkey25 that reported IAH to vary between 31% and even 94% among 
people with type 2 diabetes on insulin. Part of this discrepancy may result 
from differences between questionnaires, thus potentially identifying different 
subgroups. We used the Dutch modified version of the Clarke questionnaire, 
which has been validated against hypoglycemic clamps in people with type 1 
diabetes.17 The methods by Gold and Clarke have a good mutual concordance 
and good predictability for biochemical hypoglycemia, but correlate less well 
with the method used in Denmark.26 The latter method has been criticized for 
overestimating the prevalence of IAH.26,27
IAH was almost as prevalent in people with type 2 diabetes managed by primary 
care physicians as in those managed in secondary/tertiary care centers. The 
prevalence of severe hypoglycemia was slightly higher in secondary/tertiary 
care when compared with primary care. In fact, the association between type 
of care and severe hypoglycemia was completely lost after correction for age, 
sex, diabetes duration and HbA1c. Conversely, use of a complex insulin regimen 
increased the risk for both IAH and severe hypoglycemia, which was independent 
of where they received their care. The size and diversity of our cohort enabled us 
to also uncover non-Caucasian ethnicity and having no partner as independent 
new determinants of severe hypoglycemia and IAH, respectively, in people with 
type 2 diabetes, whereas we found no evidence for associations with smoking, 
as reported previously.23 
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Use of metformin was independently associated with lower odds of severe 
hypoglycemia in our population, which corroborates findings of a recent large 
cohort study.28 The underlying mechanism explaining this observation remains 
to be determined. Metformin has been shown to modestly enhance the release 
of growth hormone during hypoglycemia, but not that of other counterregulatory 
hormones.29 Alternatively, metformin-induced increases in plasma lactate 
may preserve brain function during hypoglycemia, thus potentially providing 
protection against severe hypoglycemia.30,31 In univariate analysis, we also 
found an inverse relationship between use of sulfonylureas and IAH or severe 
hypoglycemia. Since particularly long-acting sulfonylureas are associated with 
increased risks of hypoglycemia,32,33 this seemingly paradoxical finding is best 
explained by reverse causality. Indeed, it is highly likely that sulfonylureas were 
stopped after intensifying insulin therapy, in accordance with international 
guidelines,34 or after experiencing severe or frequent hypoglycemic events, and 
not even commenced in patients thought to be at increased risk of hypoglycemia. 
Our study has clinical implications as it shows that both IAH and severe 
hypoglycemia are common in people with type 2 diabetes on insulin therapy, 
even in those using basal insulin therapy alone or managed in primary care. 
Remarkably, although the prevalence of IAH in type 2 diabetes is at least twofold 
lower than what has been reported in type 1 diabetes, the occurrence of severe 
hypoglycemia was at least of the same magnitude.10,11,35,36 A lack in education 
about hypoglycemia focused on this population may explain at least a part of 
this discrepancy. The symptomatology of hypoglycemia may differ in elderly 
people with type 2 diabetes, whereas those with type 1 diabetes are usually 
younger, have longer experience with insulin treatment and consequently 
may already have been educated more intensively and more frequently about 
hypoglycemia.37,38 Some other risk factors for IAH in our study, for example 
non-Caucasian ethnicity, may also be partly explained by an educational gap. 
Focused education may reduce the burden of hypoglycemia and its potentially 
harmful consequences (eg, falls), as well as the associated risk of cardiovascular 
morbidity and mortality.39-41
Strengths of our study include the size of the cohort, being the largest to date 
in which the prevalence of IAH in type 2 diabetes has been determined and its 
national coverage due to the collaboration of all academic medical centers in the 
Netherlands. The inclusion of primary, secondary and tertiary care patients and 
the use of standardized protocols for data collection increase its generalizability. 
Our study also has limitations. Based on selection by academic centers, there 
may be an overrepresentation of complicated tertiary care patients. However, 
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it should be noted that most previous studies also collected data in academic 
centers.6,13,22 Second, the questionnaire we used to estimate IAH has not formally 
been validated in type 2 diabetes, but this applies to all questionnaires currently 
used for this purpose. Future research is needed to validate the questionnaire in 
patients with type 2 diabetes. Finally, we did not measure C-peptide values, the 
presence of which has been associated with lower hypoglycemia risks in people 
with type 1 diabetes,42 and most data were collected before the widespread use 
of continuous glucose monitoring techniques.
In conclusion, IAH and severe hypoglycemia are relatively common among 
people with type 2 diabetes treated with insulin, particularly when managed 
with an intensified regimen, but independent of whether this is applied in 
primary, secondary or tertiary care. Greater awareness for IAH and severe 
hypoglycemia in people with type 2 diabetes on insulin is needed, with special 
attention for people without a partner or with non-Caucasian ethnicities. 
Appropriate education to reduce the risk of hypoglycemia in people with type 2 
diabetes on insulin seems warranted, although this remains to be investigated. 
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Supplementary file
Supplemental Fig. S1. Total score on Clarke questionnaire
Supplemental Table S1. Clinical characteristics of the study population 
Total (N=2350)
Sex
   Men 1390 (59.1)
   Women 960 (40.9)
Age (years) 61.1 ± 10.4 
   <60 years 970 (41.3)
   60-70 years 895 (38.1)
    >70 years 485 (20.6)
Diabetes duration (years) 14.8 ± 9.2
   <5 years 262 (11.9)
   5-10 years 471 (21.4)
   10-20 years 927 (42.2)
   >20 years 537 (24.4)
HbA1c (%) (mmol/mol) 7.9 ± 1.4 (62.5 ± 14.8) 
   <7.0% (53 mmol/mol) 565 (25.2)
   7.0 - 8.0% (53 – 64 mmol/mol) 801 (35.8)
   >8.0% (64 mmol/mol) 874 (39.0)
Insulin treatment
   Basal only 478 (20.3)
   Pre-mixed 379 (16.1)
   Basal-bolus 1490 (63.4)
Oral glucose lowering medication 1523 (64.8)
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Purpose: Automated bolus calculation may benefit patients with poorly 
controlled type 1 diabetes who are relatively new to continuous subcutaneous 
insulin infusion (CSII). This study investigated the effect of automated bolus 
calculation on glucose variability, glucose control and diabetes-related quality 
of life in patients with reasonably well-controlled type 1 diabetes, accustomed 
to treatment with CSII for several years.
Methods: This was an open-label, single center study among 32 patients 
(mean age, 45.9 [15.1] years; 34% male; disease duration, 27.3 [12.9] years; 
glycosylated hemoglobin [HbA1c] level, 64.6 [12.5] mmol/mol [8.1% (1.1%)]; 
CSII treatment, 9.0 [7.8] years), who were randomly assigned to receive 4 
months’ treatment with a bolus calculator (n=14) or continuation of standard 
care without a bolus calculator (n=18). All participants received dietary 
counseling on carbohydrate counting. Primary outcome was glucose variability, 
as assessed by the SD of 7-point glucose profiles. Secondary outcomes included 
HbA1c, rate of (severe) hypoglycemia, and diabetes-related quality of life. 
Findings: After 4 months of follow-up, glucose variability had improved in the 
bolus calculator group compared with the control group (change, -0.8 [0.9] 
vs. 0.1 [0.9] mmol/L; P = 0.030). Mean glucose levels did not change in either 
group (0.4 [1.1] vs. 0.3 [0.9] mmol/L; P = 0.95). There were also no differences 
in change in hypoglycemia rate (-0.6 [1.6] vs. -0.4 [1.6] events per patient per 
week; P = 0.67), HbA1c value (-0.5 [6.6] versus -4.9 [10.6] mmol/mol; P = 0.21) or 
diabetes-related quality of life between the bolus calculator and control group. 
Implications: Use of a bolus calculator modestly improved glucose variability 
in this relatively small group of patients with longstanding type 1 diabetes on 
CSII but did not affect other parameters of glycemic control or diabetes-related 
quality of life. 
Keywords: continuous subcutaneous insulin infusion, bolus calculator, insulin 
therapy, glucose variability, type 1 diabetes 
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Introduction
Various large-scale clinical trials have shown the importance of near-
normalization of glucose control to reduce the risks of microvascular 
complications in individuals with diabetes.1,2 Intensive insulin therapy is 
paramount to achieving such good glycemic control in patients with type 1 
diabetes and in those with prolonged type 2 diabetes approaching the insulin-
deficient state.
Optimal insulin therapy requires patients to estimate the amount of prandial 
insulin before each meal according to several factors, including current 
glucose level, anticipated carbohydrate intake, insulin-to-carbohydrate ratio 
(ICR), estimated insulin sensitivity, target blood glucose level and anticipated 
physical activity.3 Adjustment of the insulin dose to carbohydrate intake has 
shown improvement in glycemic control, treatment satisfaction and patient’s 
wellbeing.4,5 Previous studies, however, have shown that more than one half of 
the patients estimate their prandial insulin dose incorrectly,6,7 many because 
they fear injecting too much insulin and causing hypoglycemia.8 Patients with 
poor numeracy skills have higher glycosylated hemoglobin (HbA1c) levels 
compared with patients with good numeracy skills.9,10
Automatic bolus calculators have emerged to aid in insulin bolus estimation, 
taking into account individualized ICR and insulin sensitivity factor (ISF), as 
well as the effect of previously administered insulin (ie, insulin on board). In 
daily practice, however, such bolus calculators are used by a minority of adult 
patients receiving CSII. There is still uncertainty about the benefit of automated 
bolus calculation. Some studies have shown improvements in glycemic control11 
and quality of life3,12 in poorly controlled patients treated with CSII or multiple 
daily injections (MDIs),13-15 16-18 but others have not.17,19 In most studies, however, 
extensive education on carbohydrate counting accompanied the initiation of 
the bolus calculator, which was not routinely provided in the control situation. 
In addition, many participants in studies involving CSII were new to this form 
of treatment, and most studies excluded participants with (relatively) good 
glucose control.12,16,20
The objective of the present study was to investigate whether a bolus 
calculator could still benefit patients with stable CSII treatment, for whom 
improvement of already  moderate to good glycemic control is not the primary 
aim of treatment. We hypothesized that in such cases, the use of bolus calculation 
would decrease glucose variability, reduce the hypoglycemic burden and, 
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consequently, improve diabetes-related quality of life without deteriorating 
glucose control. To test this hypothesis, we conducted a randomized controlled 
open-label trial in patients with diabetes treated by CSII, in which both groups 
received (repeated) dietary counseling at the start. 
Patients and methods 
Study Design
This 16-week, randomized controlled, single-center, open-label study 
was performed at the Radboud University Medical Center in Nijmegen, the 
Netherlands, between February 2014 and May 2016. The study was approved by 
the local institutional review board and performed according to the principles of 
the Declaration of Helsinki. All participants provided written informed consent.
Study Population 
Patients with type 1 diabetes treated with CSII were recruited from the 
outpatient clinic. People were eligible for participation in the study when 
they met the following criteria; treatment with CSII for at least 6 months, age 
between 18 and 60 years, HbA1c value <86 mmol/mol (10%), disease duration 
>2 years, and a total daily insulin dose <1 U/kg. Key exclusion criteria were 
current use of a bolus calculator, inability or unwillingness to perform frequent 
blood glucose measurements, pregnancy or intention to become pregnant, 
prednisone treatment, a recent cardiovascular event, or the presence of severe 
microvascular complications. Although we initially invited patients with long-
duration type 2 diabetes to participate, only 2 patients were enrolled, both of 
whom were randomized to the bolus calculation group. Because of the low 
numbers and this imbalance, we decided to exclude these patients from analysis.
Study Procedure 
At the screening visit, participants completed various diabetes-related quality 
of life questionnaires (Confidence in Diabetes Self-Care scale, Hypoglycemia 
Fear Survey, Problem Areas in Diabetes questionnaire), and HbA1c levels were 
measured. All participants received dietary advice from a dietician concerning 
carbohydrate counting and insulin bolus calculation; the knowledge thus 
acquired was tested by examination. When participants failed this test, they 
were scheduled for a second visit by a dietitian. Subsequently, participants 
were randomized to either the bolus calculator group or the control group. For 
random allocation concealment, we used opaque, sealed envelopes and blocks 
of 4 subjects. 
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The second visit occurred 2 weeks later. Participants collected 7-point 
blood glucose profiles for 5 days before the visit and kept a diary about their 
carbohydrate intake during these days. Participants randomized to the bolus 
calculator group were consulted by a diabetes educator to receive information 
about use of the bolus calculator. ICR and ISF were calculated based on the 
insulin total daily dose (TDD), and ratios were programmed into the bolus 
calculator. The ICR was calculated using the 500 rule (ICR=500 divided by TDD) 
and ISF using the 100 rule (ISF=100 divided by TDD).19,21,22 Target blood glucose 
levels were determined individually, and insulin on board time was set at 4 hours 
for each participant. All participants were advised to maintain their current 
lifestyle with respect to diet and physical exercise during the study period. 
After 2 months, participants again collected 7-point blood glucose profiles for 
5 days, and adjustments to pump settings were performed if necessary. 
Final assessment took place after 4 months at the outpatient clinic. Participants 
again collected 7-point blood glucose profiles for 5 days and completed a diary 
about carbohydrate intake. Blood samples were collected to determine HbA1c 
levels, and diabetes-related quality of life was reassessed with aforementioned 
questionnaires.
Study Outcomes
The primary end point of this study was the change in glucose variability, 
calculated from the 7-point glucose profiles. Secondary end points were 
changes in HbA1c, low blood glucose index (LBGI), high blood glucose index 
(HBGI), the total amount of insulin used, incidence of (severe) hypoglycemia, 
diabetes-related quality of life, and presence of impaired awareness of 
hypoglycemia. 
Measurements
For blood glucose measurements, patients used their own glucose meters. 
Patients continued using their current insulin pump, and they started using the 
bolus calculator that was provided by this pump. Hypoglycemia was defined as 
a self-measured glucose level <3.0 mmol/L and severe hypoglycemia as those 
events requiring assistance from another person for recovery.23 HbA1c levels 
were measured by using the TOSOH G8 HPLC-analyzer, distributed by Sysmex 
Corporation (Kobe, Hyōgo Prefecture, Japan). 
Diabetes-related quality of life was assessed by use of questionnaires. The 
Hypoglycemia Fear Survey is divided into 2 sub-questionnaires; fear that is 
manifested in certain behavior (15 items) and in certain worries (13 items). 
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The behavior subscale is not validated and was therefore not used. The worries 
subscale has good reliability (Cronbach’s α=0.92). It has a cutoff score of 20, 
with higher scores indicating more fear of hypoglycemia.24,25 The Confidence 
in Diabetes Self-Care scale asks patients to indicate their level of confidence 
regarding daily activities related to their diabetes (20 items). Scores range from 
0 to 100, with higher scores reflecting more confidence in diabetes self-care. 
This test has a high internal consistency in Dutch patients (Cronbach’s α=0.86) 
and high test-retest reliability (Spearman’s r=0.85; p<0.0001).26 The Problem 
Areas in Diabetes questionnaire consists of 20 items with possible diabetes-
related problems, for which patients need to rate how much of a problem these 
items are at that moment in their lives. Scores range from 0 to 100. Higher scores 
indicate more diabetes related distress, and a score ≥40 is related to severe 
diabetes related distress. Internal consistency (Cronbach’s α=0.93-0.95) and 
test-retest reliability (Pearson’s correlation=0.83) are high.27,28 
We also assessed the status of awareness of hypoglycemia, using the Dutch-
modified translation of the Clarke questionnaire that was validated with 
hypoglycemic glucose clamps.29,30 
Calculations and Statistical Analysis 
Glucose variability was defined by the SD of 7-point blood glucose profiles 
over 5 consecutive days. The ICR, reflecting the amount of carbohydrates that 
can be processed by 1 unit of insulin, was calculated by dividing the amount of 
carbohydrates ingested by the amount of insulin injected at that time. The ISF, 
reflecting the blood glucose level response (in millimoles per liter) to 1 unit of 
insulin injected, was calculated by dividing the fall in blood glucose level by the 
amount of insulin used. The LBGI and HBGI were calculated using the EasyGV 
Version 9.0.R2 (available free for noncommercial use at www.easygv.co.uk) to 
assess the risks of hypoglycemia and hyperglycemia, respectively.31
We calculated that for the detection of a 20% decrease in glucose variability at 
a 2-sided significance level of 0.05 with a power of 80%, the total number of 
subjects needed would be 14 per group. To account for drop-out, we thus aimed 
to enroll a total number of 30 subjects. 
Data were analyzed using IBM SPSS statistics version 22 (IBM SPSS Statistics, 
IBM Corporation, Armonk, New York). In total 187 people were screened for 
participation in this study, 48 of whom were potentially eligible. Fourteen 
subjects were excluded or withdrew consent before randomization. Hence, 
the analysis included 32 participants: 14 randomized to the bolus calculator 
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group and 18 to the control group. We performed an intention-to-treat analysis 
on the remaining 32 patients. Missing data were imputed using inference 
methods. Student’s independent 2-sample t tests were used to compare the 2 
study groups and paired-samples t tests for the calculation of within-groups 
changes over time. Two-way ANOVA analyses were used to compare the mean 
differences in blood glucose level and SDs between the groups. Pearson’s χ2 
analyses were used for categorical variables. A P value of <0.05 was considered 
statistically significant.
Results 
All patients randomized to treatment completed the study (Figure 1). Baseline 
characteristics of the study participants are presented in Table I. Groups were 
comparable with regard to age, sex, disease duration, HbA1c level, and history of 
microvascular complications. 
Fig. 1. Flow diagram showing patient selection. HbA1c = glycosylated hemoglobin
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Table I. Baseline characteristics. Unless otherwise indicated, data are mean (SD) or median (quartile 
1, quartile 3) 
 Bolus calculator (n=14) Control group (n=18) 
Male 6 (43%) 5 (28%)
Age, y 48 (15) 45 (15)
Weight, kg 81.7 (12.3) 76.6 (13.7)
Height, cm 172.4 (9.5) 173.1 (8.8)
Body mass index, kg/m² 27.6 (4.5) 25.6 (4.7)
Disease duration, y 28 (14) 27 (12)
Duration insulin pump therapy, y 7 (3,13) 6 (2,16)
Total insulin dose, IU 40 (13) 41 (23)
Basal/bolus insulin ratio 61/39 58/42
HbA1c, mmol/mol 65 (11) 64 (14)
HbA1c, % 8.1 (1.0) 8.0 (1.3)
History of microvascular complications 6 (43%) 6 (33%)
Retinopathy 4 (29%) 5 (28%)
Neuropathy 3 (21%) 3 (17%)
Nephropathy 2 (14%) 3 (17%)
History of peripheral vascular disease 1(7%) 2 (11%)
History of cardiovascular events 0 0
Changes in Glycemic Parameters
The 7-point glucose profiles averaged over 5 days are shown in Figure 2. There 
were no differences between mean glucose levels at baseline and end of the 
study for either the bolus calculator group (8.3 [1.2] vs. 8.7 [1.4] mmol/L; 
difference, 0.4 mmol/L [95% CI, -0.4 to 1.1]; P = 0.58) or the control group 
(8.2 [1.4] vs. 8.6 [1.5] mmol/L; difference, 0.3 mmol/L [95% CI, -0.2 to 0.9]; 
P = 0.07) at any time point or between the groups (difference, 0.03 mmol/L 
[95% CI, -0.8 to 0.9]; P = 0.95). Glucose variability, as assessed by the SD of 
these profiles, declined significantly in the bolus calculator group over time but 
did not change in the control group (Figure 3). This change in glucose variability 
in the bolus calculator group was significantly different from that in the control 
group (-0.8 [0.9] vs. 0.1 [0.9] mmol/L; difference, -0.9 mmol/L [95% CI, -1.7 to 
-0.1]; P = 0.030). 
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HbA1c fell slightly in both the bolus calculator and control group, but neither 
effect nor the difference between groups reached statistical significance (-0.5 
[6.6] vs. -4.9 [10.6] mmol/mol; difference, 4.3 mmol/mol [95% CI, -2.5 to 11.2]; 
P = 0.21). LBGI and HBGI also did not change (neither in the bolus calculator 
group nor in the control group). LBGI did not differ between groups (-1.3 [4.8] 
vs. 0.3 [5.2]; difference, -1.6 [95% CI, -5.4 to 2.2] for bolus calculator group vs 
control group, respectively; P = 0.39). HBGI also did not differ between groups 
(1.3 [5.3] vs. 0.1 [3.7]; difference, 1.3 [95% CI, -2.1 to 4.6] for bolus calculator 
group vs the control group; P = 0.45) (Table II). 
Fig. 2. Mean blood glucose levels based on 7-point glucose profiles before (open circles) and at 




Fig. 3. Glucose variability, defined as the mean SD of glucose profiles, before and at the end of study, 
for the bolus calculator group (closed circles) and control group (open circles), * = P<0.05.
Table II. Low blood glucose index (LBGI) and high blood glucose index (HBGI)






Baseline 7.3 (3.9) High 7.5 (5.0) High 0.88
End of study 6.0 (3.3) High 8.1 (5.5) High 0.21
HBGI
Baseline 10.2 (4.7) Moderate 9.6 (3.9) Low 0.68
End of study 11.5 (4.3) Moderate 10.7 (4.5) Moderate 0.61
* Risk of hypoglycemia/hyperglycemia;  Data are shown as mean (SD). Calculation of risk 
scores for LBGI: index ≤ 1.1 reflects a minimal risk, index >1.1 to ≤2.5 reflects a low risk, index 
>2.5 to ≤5.0 reflects a moderate risk, and index >5.0 reflects a high risk of hypoglycemia. 
Calculation of risk scores for HBGI: index <5.0 reflects a minimal risk, index >5.0 to ≤2.5 reflects 
a low risk, index >2.5 to ≤5.0 reflects a moderate risk, and index >5.0 reflects a high risk of 
hyperglycemia.
Hypoglycemia Rates
Frequency of biochemical hypoglycemia decreased numerically in the bolus 
calculator group with 0.6 event per week (95% CI, -0.3 to 1.5; P = 0.19) and 
with 0.4 event per week (95% CI, -0.5 to 1.2; P = 0.39), but neither finding 
reached statistical significance.  One patient in each group experienced a 
severe hypoglycemic event. However, the event in the bolus calculator group 
occurred directly after randomization before the patient had started to use the 
bolus calculator.
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Table III. Secondary outcome measurements: quality of life. Values are given as mean (SD).
Variable Bolus Calculator group Control group P
CIDS
Baseline 86 (6) 87 (6) 0.72
End of study 85 (7) 87 (7) 0.34
PAID
Baseline 20 (20) 22 (15) 0.82
End of study 19 (17) 23 (17) 0.57
HFS
Baseline 16 (9) 14 (8) 0.72
End of study 15 (8) 16 (10) 0.81
CIDS = Confidence in Diabetes Self-Care scale (scores range from 0-100, with higher scores 
reflecting more confidence); HFS = Hypoglycemia Fear Survey (scores range from 0-52, with 
higher scores reflecting more fear of hypoglycemia); PAID = Problem Areas in Diabetes 
questionnaire (scores range from 0-100, with higher scores reflecting more diabetes related 
distress).
Diabetes-related Quality of Life
Neither fear of hypoglycemia nor diabetes-related problems or confidence in 
diabetes self-care changed during follow-up in the bolus calculator group or in 
the control group; there were no differences between the groups (Table III). The 
average score on the modified Clarke questionnaire changed with -0.2 (95% CI, 
-0.3 to 0.8; P = 0.39) in the bolus calculator group and with -0.1 (95% CI, -0.3 to 
0.5; P = 0.72) in the control group. None of the patients in either group changed 
from normal awareness to impaired awareness of hypoglycemia or vice versa 
during the study period. 
Subgroup Analysis
Subgroup analyses were performed for the primary outcome based on age (≤50 
vs >50 years), sex, duration of CSII therapy (≤6 vs >6 years), and HbA1c level 
(≤64 vs >64 mmol/mol). The decline in glucose variability overall appeared 
to be mainly driven by the subgroup of patients aged > 50 years, in whom the 
bolus calculator reduced glucose variability by 1.1 mmol/L (95% CI, -2.5 to 0.3) 
versus an increase of 0.8 mmol/L (95% CI, -0.04 to 1.6) in those randomized to 
the control group (difference, -1.9 mmol/L [95% CI, -3.2 to -0.5]; P = 0.019). 
There was no change in glucose variability based on differences in sex, duration 




The main finding of the present study is that short-term use of a bolus calculator 
in patients with type 1 diabetes on CSII for several years had a modest beneficial 
effect on glucose variability but did not change overall glucose control, incidence 
of hypoglycemia, or diabetes-related quality of life. We also found a negligible 
effect of the bolus calculator on the prevalence of impaired awareness of 
hypoglycemia. 
Our study is in agreement with several previous studies showing no or minimal 
effects of the use of a bolus calculator on glucose control. One study in children 
and adolescents with type 1 diabetes on CSII found a borderline decrease 
(P = 0.056) in glucose variability after 1 year of bolus calculator use but observed 
no change in HbA1c levels.
19 Similarly, Gross et al17 found no differences in 
average deviation of postprandial glucose levels from target in patients receiving 
CSII using a bolus calculator. Another study also showed no improvement in 
glucose control in patients treated with MDI and a bolus calculator.12 We found 
no differences in frequency of hypoglycemia after the start of using a bolus 
calculator, again in line with results of other studies.16,17,19 
In contrast, other studies have reported an improvement in glucose control 
after use of a bolus calculator in patients with CSII. Yamada et al16 showed a 
drop in HbA1c level in patients with type 1 diabetes who were started on a 
bolus calculator. They included patients new to CSII therapy and use of a bolus 
calculator. The differences in design may partially explain the differences; 
although the study by Yamada et al included new patients, our patients were on 
CSII for almost 10 years. Garg et al18 found improved glucose control in patients 
using insulin guidance software (experimental group) because of significant 
more glucose values within the target range (3.89-8.33 mmol/L). However, 
patients in the experimental group also performed a significantly higher number 
of self-monitoring of blood glucose (SMBG) tests.
We found no improvement in diabetes-related quality of life after use of 
a bolus calculator, which is in agreement with several other studies that 
examined diabetes-related quality of life.11,20 The exception is 2 studies showing 
improvement in treatment satisfaction, but not in other areas, among patients 
treated with MDI.3,12 It is plausible that quality of life in our participants was 
already at such a high level that further improvement could not be achieved. 
Indeed, baseline scores of <25 for the Problem Areas in Diabetes questionnaire 
in our participants reflect very little diabetes-related distress. Alternatively, 
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although many patients report that the bolus calculator is easy to use and 
preferred over self-calculations to determine insulin doses,17 the associated 
need for self-measurement and check for carbohydrate content may diminish 
enthusiasm for the device. 
In our study, subgroup analyses showed consistent results in change in glucose 
variability. Further research is needed to determine if elderly patients (aged 
>50 years) benefit more from use of a bolus calculator when compared with 
younger patients.   
There are a number of potential explanations for the limited benefits of 
introducing automated bolus calculation in our study. First, patients in our study 
had a mean disease duration of 27 years, and they were treated with CSII for 
almost 10 years on average. Given this long duration, patients may already be 
familiar with the principles of carbohydrate counting  and estimating required 
insulin doses. It is also possible that they felt less comfortable with and were 
therefore less likely to rely on advice from the bolus calculator than on their 
own estimations. We did not specifically select patients experiencing extreme 
glucose excursions and excluded patients with very high HbA1c levels but 
not those with optimal glycemic control (HbA1c levels <53 mmol/mol [7%]). 
This approach not only explained why patients in our study were  moderately 
controlled but also made it harder to show added benefit of an intervention 
aimed at improving glycemic management. Therefore, although not supported 
by our subgroup analysis, we cannot exclude a potential beneficial effect of 
automated bolus calculation in patients with poor glucose control or those 
recently starting insulin pump therapy. 
Our study has limitations. The study was randomized and controlled but not 
blinded. However, a completely blinded trial would require a complicated 
design that would in itself jeopardize generalization. Although based on a 
power calculation, the number of study subjects was relatively small and from 
1 center only, which limits generalizability. Glucose data were collected from 
SMBG tests, which may provide less information than continuous glucose 
monitoring (CGM). However, current reimbursement restrictions limit 
widespread implementation of CGM in clinical practice, and thus most patients 
need to rely on SMBG. The use of SMBG therefore better approaches real-world 
practice in most patients compared with CGM. Another limitation is the relative 
short duration of the study. However, although the durability of the effects of 
automated bolus calculation remains to be determined, 4 months was sufficient 
to detect differences in the primary outcome. In addition, most other studies 
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examining bolus calculators were of similarly short duration.11,12,17 Strengths 
of this study are the randomized controlled design and the homogeneity of the 
study population. Furthermore, our control group received equally intensive 
dietary education on carbohydrate counting; thus, any differences between the 
groups could be solely attributed to the bolus calculator per se.  
Conclusions
Among patients with longstanding diabetes and  moderate glucose control 
on CSII, additional use of a bolus calculator had limited beneficial effects on 
glucose variability but did not affect other glycemic end points or diabetes-
related quality of life. As such, we believe that automated bolus calculation fits 
in a tailor-made personalized treatment strategy for individuals with sufficient 
motivation for its use rather than being implemented according to a one-size-
fits-all approach.
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Effect of the GLP-1 receptor agonist 
exenatide on impaired awareness  
of hypoglycemia in type 1 diabetes;  
a randomized controlled trial
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Context: Impaired awareness of hypoglycemia (IAH), resulting from habituation 
to recurrent hypoglycemia, can be reversed by strict avoidance of hypoglycemia. 
Adjunctive treatment with glucagon-like peptide-1 receptor agonists may 
reduce glucose variability, hence  lower the risk of hypoglycemia and improve 
awareness. The aim of our study was to investigate the effect of exenatide on 
awareness of hypoglycemia in patients with type 1 diabetes and IAH. 
Methods: This was a randomized double-blind, placebo-controlled crossover 
trial. Ten patients with type 1 diabetes and IAH were included [age 38.5 ± 4.4 
years; 40% males; glycated hemoglobin 7.2% ± 0.4 % (55.2 ± 4.8 mmol/mol)]. 
Patients were treated with exenatide 5µg twice daily (first two weeks), followed 
by 10µg twice daily (remaining four weeks) or matching placebo, with a four-
week washout period. Patients wore blinded glucose sensors in the final weeks 
and modified hyperinsulinemic normoglycemic-hypoglycemic glucose clamps 
(nadir 2.5 mmol/L) were performed at the end of each treatment period. 
Results: Treatment with exenatide caused body weight to decrease compared 
with placebo (-3.9 ± 0.9 vs 0.6 ± 1.2 kg, P = 0.047). Exenatide did not change 
mean 24-hour glucose levels (8.3 ± 0.4 vs 8.5 ± 0.3 mmol/L, exenatide vs 
placebo, P = 0.64), median (interquartile range) percentage of time spent in 
hypoglycemia [15.5 (4.5, 25.5) vs 7.8 (4.4, 17.1)%, P = 0.11] and frequency of 
hypoglycemia (15.8 ± 3.7 vs 12.1 ± 3.5, P = 0.19). Symptom scores in response 
to clamped hypoglycemia were similar between exenatide [median change 1.0 
(-1.5, 7.0)] and placebo [4.5 (1.5, 5.8), P = 0.08].
Conclusions: Six weeks of treatment with exenatide did not improve awareness 
of hypoglycemia in patients with type 1 diabetes and IAH. (J Clin Endocrinol 
Metab 104: 4143-4150, 2019)
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Introduction
Iatrogenic hypoglycemia is the most frequent acute complication of insulin 
therapy in patients with type 1 diabetes (1). Patients with type 1 diabetes 
experience on average two to three hypoglycemic events per week and one 
severe event requiring external assistance every year (2,3). Accurate and 
timely recognition of the typical symptoms of decreasing plasma glucose levels 
are of pivotal importance to prevent severe hypoglycemia. Approximately 25% 
of patients with type 1 diabetes have lost the ability to detect hypoglycemia, 
a condition referred to as impaired awareness of hypoglycemia (IAH) (4,5), 
which increases the risk for severe hypoglycemia up to sixfold (6). IAH is usually 
the end result of a process of brain adaptation  to recurrent hypoglycemia. 
Meticulous avoidance of hypoglycemia for two to four weeks can reverse this 
process, thus ameliorating symptomatic awareness of hypoglycemia (7,8). Not 
uncommonly, marked glucose variability and (too aggressive correction of) 
recurrent hyperglycemia are at the basis of the hypoglycemic burden as a whole, 
thus contributing to both the development and the persistence of IAH (9-11). 
Exenatide was the first glucagon-like-peptide-1 receptor agonist (GLP-1RA) to 
be used for the treatment of type 2 diabetes. GLP-1RAs improve glycemic control 
by several mechanisms, including suppressed glucagon release, delayed gastric 
emptying, and decreased food intake (because of early satiety) (12-15). By 
virtue of their pharmacology, these agents have their most profound glucose-
lowering effect on postprandial glucose excursions (16), but do not increase 
the risk of hypoglycemia (17). More stability in day-to-day glucose control with 
reduced need to (over)correct hyperglycemia may decrease  hypoglycemic 
exposure, which would particularly benefit patients with IAH. GLP-1 and 
GLP-1RAs have a neutral effect on counterregulatory hormone and symptom 
responses to hypoglycemia, both in healthy subjects and in patients with type 1 
or type 2 diabetes (17-20). However, the effect of GLP1-RAs on these responses 
has not been examined in patients with type 1 diabetes and IAH. Furthermore, 
their effect on the recovery from and in particular the glucose excursion after 
hypoglycemia has not been examined. We posited that reduced exposure to 
hypoglycemia during treatment with GLP-1RAs will improve awareness of and 
recovery from hypoglycemia in patients with type 1 diabetes and IAH, whereas 
the pharmacology of GLP-1RAs will limit hyperglycemic glucose excursions 
following hypoglycemia. The aim of this study was to investigate the effect of 
exenatide (GLP-1RA) treatment on symptom scores in response to insulin-
induced hypoglycemia in patients with type 1 diabetes and IAH.
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Materials and methods 
Study design
This was an investigator-initiated randomized double-blind, placebo-controlled 
crossover intervention trial that was performed at the Radboud University 
Medical Center in Nijmegen, Netherlands. The study was approved by the local 
institutional review board and performed according to the principles of the 
Declaration of Helsinki. All participants provided written informed consent. 
This research was conducted with support from AstraZeneca BV, Netherlands.
Study population
Patients with type 1 diabetes were recruited from the outpatient diabetes clinic of 
the Radboud University Medical Center between January 2017 and March 2018. 
Patients were eligible for participation when they met the following criteria; type 
1 diabetes mellitus for one year or more; age between 18 and 75 years; glycated 
hemoglobin (HbA1c) 6 to 9% (42 to 75 mmol/mol); insulin treatment according 
to basal-bolus insulin regimen; body mass index (BMI) 19 to 40 kg/m2; and the 
presence of IAH as assessed by a score of three or more on the Dutch version 
of the Clarke questionnaire (21). Key exclusion criteria were current treatment 
with or known intolerance to incretin-based therapy, treatment with coumarin 
derivates or antibiotics, treatment with glucose- or immune-modifying agents, 
history of cardiovascular disease, diabetes-related complications (except for 
background retinopathy and asymptomatic peripheral neuropathy), and total 
daily insulin dose requirements <20 units unless on pump treatment. 
Study procedure 
Participants were asked to come to the outpatient clinic for a medical screening, 
including medical history and standard physical examination (including weight, 
height, blood pressure, pulse rate and screening for peripheral neuropathy). 
We also determined kidney function (serum creatinine) and HbA1c if this had not 
been done within the last six months. 
After inclusion, patients were randomly assigned to treatment with exenatide 
or placebo for six weeks in a crossover fashion, with a washout period of four 
weeks in between. Randomization was done by a computer program with the 
use of blocks of two subjects, to ensure that equal numbers of subjects would 
be treated with exenatide of placebo first. Random allocation sequence was 
done using a computer software program that generated the random sequence. 
Participants were enrolled by the investigator and were assigned to exenatide 
or placebo treatment first according to a randomization list that was managed 
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by the pharmacy department of our hospital, ensuring that participants and 
investigators were blinded to treatment assignment. After the start of the study 
medication, patients were instructed to reduce prandial insulin levels by 20%. 
Participants were asked to perform four-point daily blood glucose profiles and 
to keep a glucose diary for the duration of the study. Insulin doses were adjusted 
according to the glucose profiles, aiming for fasting and pre-meal blood glucose 
levels of 4 to 7 mmol/L without the occurrence of hypoglycemia. Exenatide and 
placebo injections were dosed 5 µgf twice daily for the first two weeks of the 
study, and when tolerated, the dose was increased to 10 µg twice daily for the 
remaining four weeks. Insulin doses were then decreased by another 20% and 
adjusted according to the glucose profiles. In weeks one, two and four, insulin 
dose adaptations and potential side effects were documented by telephone 
consultation. Patients recorded any hypoglycemic event in their glucose diary 
and whether they needed help from someone. During the final week of each 
treatment period, subjects completed seven-point glucose profiles, and wore 
a blinded continuous glucose monitor (CGM) (Dexcom G4; Dexcom Inc., San 
Diego, CA) for five days. 
At the end of each treatment period, subjects underwent a hyperinsulinemic 
euglycemic hypoglycemic clamp (nadir 2.5 mmol/L). Participants presented at 
8.00 AM at the clinical research facility after an overnight fast, having abstained 
from alcohol, caffeine, and smoking for 24 hours and from strenuous exercise 
for 48 hours. They received instructions to avoid (nocturnal) hypoglycemia the 
day before the clamp by reducing basal insulin dose during the night and an 
extra blood glucose measurement at 2.00 AM. In the case of hypoglycemia, the 
clamps were rescheduled. When the patients arrived at the research facility, two 
intravenous cannulas were inserted into the antecubital vein of each forearm. 
One forearm was placed in a heated box (55ºC) so that arterialized venous blood 
could be obtained to measure glucose levels every five minutes. The cannula 
in the contralateral arm was used for infusion of glucose 20% (Baxter B.V., 
Deerfield, IL) and insulin (insulin aspart; Novo Nordisk, Bagsvaerd, Denmark). 
Glucose levels were determined using Biosen C-Line (EKF Diagnostics, Cardiff, 
U.K.) (22). Baseline hyperglycemia was corrected as needed with a small bolus 
of insulin. Subsequently, a hyperinsulinemic (60 mU·m-2·min-1) euglycemic 
(5.0 mmol/L) hypoglycemic (2.5 mmol/L) glucose clamp was initiated. Blood 
samples for the measurement of catecholamines, insulin, glucagon, cortisol 
and GHs were obtained at baseline, after 30 minutes of euglycemia, twice during 
hypoglycemia (after 20 and 45 minutes), and after recovery from hypoglycemia 
(45 minutes after hypoglycemia). After the euglycemic phase (30 minutes), 
glucose levels were allowed to decrease to 2.5 mmol/L over ~35 minutes and 
88
Chapter 5
were maintained there for another 45 minutes. At the end of the hypoglycemic 
phase, participants were asked to estimate their current glucose levels, and to 
eat as much as they thought would be necessary to recover from hypoglycemia. 
Insulin infusion was stopped at that moment and glucose infusion was tapered 
until cessation over 35 minutes. Glucose levels were measured until 45 minutes 
after hypoglycemia, unless patients were still hypoglycemic at that point, then 
measuring of glucose levels continued until euglycemic glucose levels were 
reached.  
Participants were asked to rate hypoglycemic symptom scores by a validated 
questionnaire (21) at baseline, once during euglycemia, twice during 
hypoglycemia, and once after recovery from hypoglycemia. Symptoms were 
divided into autonomic symptoms (trembling, palpitations, anxiety, sweating, 
hunger and tingling), neuroglycopenic symptoms (difficulty speaking, confusion, 
fatigue, blurred vision, feeling faint an difficulty thinking), general symptoms 
(nausea, headache, dry mouth and weakness), and dummy symptoms (pain in 
the legs and yellow vision). Symptoms were scored from 0 (none) to 6 (severe) 
(21,22). Differences in symptom scores were calculated between baseline 
and the second hypoglycemic time point (after 45 minutes of hypoglycemia). 
Participants also completed a questionnaire about appetite scores at the same 
time points during the clamp. This questionnaire consisted of a visual analog 
scale (0 to 100 mm) on which patients rated hunger, fullness, prospective 
consumption, desire to eat, and thirst (maximal score 500 mm) (23). 
Study outcomes 
The primary end point of this study was the symptom score in response to insulin-
induced hypoglycemia, measured during the hyperinsulinemic hypoglycemic 
clamps after treatment with exenatide or placebo. Secondary end points 
were changes in plasma levels of counter regulatory hormones in response to 
insulin-induced hypoglycemia, time until recovery from hypoglycemia (defined 
as a glucose level above 4.0 mmol/L), maximal glucose excursion post-
hypoglycemia, self-reported appetite scores during and after hypoglycemia, 
amount of carbohydrates and calories consumed after hypoglycemia, glucose 
variability, mean 24-hour glucose levels, and time spent in low glucose (<4.44 
mmol/L) on CGM during the final treatment weeks, glucose infusion rates 
during the hyperinsulinemic clamp, and HbA1c levels. Time in range was defined 
as glucose levels between 4.44 and 7.21 mmol/L, according to predefined 
Dexcom G4 settings. 
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Measurements 
Plasma insulin was assessed by an in-house radioimmunoassay (24). Plasma 
glucagon was measured by radioimmunoassay (Eurodiagnostica, Malmö, 
Sweden). Plasma GH and cortisol were determined using a routine analysis 
method with an electrochemiluminescent immunoassay on a Modular Analytics 
E170 (Roche Diagnostics, GmbH, Mannheim, Germany). Plasma adrenaline and 
noradrenaline were analyzed by HPLC combined with fluorometric detection 
(22). HbA1c was measured by the TOSOH G8 HPLC-analyzer (Sysmex Nederland 
B.V., Etten-Leur, Netherlands).
Statistical analysis 
A power calculation aimed at finding a 40% increase in symptom score in 
response to hypoglycemia with a power of 80% yielded a total number of 
participants of 10, where drop-outs would be replaced. Data were analyzed 
using IBM SPSS statistics version 25. We tested for normality using the Shapiro-
Wilk test and QQ plots. Paired Student t tests were used to analyze differences 
in means within groups, and Wilcoxon signed rank tests were used when data 
were not normally distributed. Serial data were analyzed by two-way repeated-
measures ANOVA. All data are expressed as the mean ± SEM, unless otherwise 
specified. A P value <0.05 was considered statistically significant. Missing data 
were imputed if possible. 
Results 
A total of 13 patients with type 1 diabetes and IAH were recruited between 
January 2017 and November 2017, with a follow-up period between February 
2017 and March 2018. One patient withdrew after six days of exenatide treatment 
because of nausea and vomiting. One patient withdrew after five weeks, while 
on placebo treatment, because of diabetic ketoacidosis not related to the study. 
One other patient assigned to placebo treatment withdrew after six weeks, 
because her endocrinologist disagreed with her participation in this study, 
although he/she was informed about the participation before start of the study 
and did not disagree at that time. As a result, a total of 10 patients were included 
and analyzed; baseline characteristics are shown in Table 1. Four patients, 
already using CGM, continued using this device in unblinded setting during 
the study. None of the results in this group differed from those on blinded CGM 





Mean 24-hour glucose levels averaged 8.3 ± 0.4 mmol/L during the final week of 
treatment with exenatide and 8.5 ± 0.3 mmol/L during the final week of treatment 
with placebo (difference, -0.24 mmol/L, P = 0.64). Median percentage of time in 
range was comparable between exenatide and placebo treatment [30.4% (22.9, 
30.4) vs 29.1% (22.3, 29.1), P = 0.45]. Glucose variability, defined as the mean 
SD, also did not differ between the two treatment periods (3.7 ± 0.3 mmol/L vs 
3.6 ± 0.3 mmol/L, exenatide vs placebo respectively, P = 0.82). HbA1c-levels did 
not change in either group. 
Insulin dose
Total daily bolus insulin doses were numerically lower during treatment with 
exenatide (15.8 ± 1.9 IU) compared with treatment with placebo (18.6 ± 2.8 IU), 
but this difference did not reach statistical significance (P = 0.20). Daily basal 
insulin doses were approximately similar between the two treatment periods 
(21.6 ± 3.2 IU vs 22.2 ± 3.4 IU, exenatide vs placebo respectively, P = 0.43). Two 
patients were on multiple daily insulin injections, with insulin glargine as basal 
insulin. Evening meal bolus insulin doses were numerically lower with exenatide 
treatment when compared with placebo, however there was no statistically 
significant difference (difference, -1.5 ± 0.7 IU, P = 0.061).
Hypoglycemia 
The frequency of hypoglycemic episodes during the six-week treatment did 
not differ according to the treatment regimen (15.8 ± 3.7 episodes vs 12.1 ± 3.5 
episodes per person, P = 0.19). The frequency of severe hypoglycemia was 1.5 
± 2.5 episodes per person during exenatide treatment and 0.4 ± 1.0 episodes 
per person during placebo treatment. Median percentage of time spent in low 
glucose on CGM was numerically higher during the final week of treatment with 
exenatide compared with placebo [15.5 % (4.5, 25.5) vs 7.8 % (4.4, 17.1), P = 
0.11], but this difference was not statistically significant.
Weight and BMI
There was a substantial change in body weight after treatment with exenatide 
compared with placebo treatment (-3.9 ± 0.9 kg vs 0.6 ± 1.2 kg, respectively, 
P = 0.047). BMI also changed after treatment with exenatide compared with 
placebo (-1.2 ± 0.3 kg/m2 vs 0.2 ± 0.3 kg/m2, P = 0.043). 
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Table 1. Baseline characteristics 
n = 10
Age, y 38.5 ± 14.0
Male, n (%) 4 (40)
Weight, kg 78.1 [68.5, 106.3]
BMI, kg/m² 25.4 [23.7, 31.7]
Abdominal circumference, cm 94.8 ± 16.6
Score on modified Clarke questionnaire 3.5 [3.0, 4.25]
Complications, n (%)
   Retinopathy 1 (10)
   Neuropathy 1 (10)
   Nephropathy 0 (0)
Duration of diabetes, y 21.7 ± 13.5
Insulin therapy, n (%)
   CSII 8 (80)
   MDI 2 (20)
Insulin dose, IU/d 46.9 ± 20.6
HbA1c, % (mmol/mol) 7.2 ± 0.4 (55.2 ± 4.8) 
Creatinin, µmol/L 69.1 ± 6.0
Data are presented as number (%), mean±SD or median [IQR]. CSII, continuous subcutaneous 
insulin infusion; MDI, multiple daily injections.
Adverse effects 
Five participants experienced nausea during treatment with exenatide; in two 
cases this was self-limiting and predominantly occurred directly after starting 
the medication. The other three participants used antiemetic drugs because 
of nausea and vomiting. In one other participant, nausea and vomiting were 
reasons to withdraw from study participation a few days after start of the 
treatment. One serious adverse event (diabetic ketoacidosis) occurred during 
placebo treatment, which was judged to be unrelated to the investigational 
medicinal product. Patients did not experience any other adverse effects during 
treatment with placebo.
Hypoglycemic glucose clamps
Glucose and insulin levels 
Mean glucose levels during the two clamps are shown in Fig. 1. Nadir plasma 
glucose levels were 2.4 ± 0.0 mmol/L during exenatide treatment and 2.5 ± 0.0 
mmol/L after placebo treatment (difference between groups 0.1 ± 0.0 mmol/L, 
P = 0.046). Mean glucose infusion rates did not differ during hypoglycemia 
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(3.8 ± 0.5 vs 3.7 ± 0.3 mg·kg-1·min-1, exenatide vs placebo, P = 0.67)  or during 
recovery after hypoglycemia (3.2 ± 0.3 vs 2.9 ± 0.2 mg·kg-1·min-1, respectively, 
P = 0.62) (Fig. 1). Glucose levels after 45 minutes of hypoglycemia averaged 2.8 
± 0.1 mmol/L during exenatide treatment and 2.9 ± 0.1 mmol/L during placebo 
treatment. Patients estimated their lowest glucose levels as 3.6 ± 0.3 mmol/L 
after exenatide treatment and as 3.4 ± 0.3 mmol/L after placebo treatment. Mean 
time until glycemic recovery was 35.0 ± 5.2 minutes after exenatide treatment 
and 31.9 ± 3.4 minutes after placebo treatment (P = 0.66). Median serum insulin 
concentrations were 72.1 (60.6, 100.0) mU/L after exenatide treatment, and 
63.9 (53.6, 156.3) mU/L after placebo treatment (P = 0.80).  
Hypoglycemic symptoms and counter regulatory hormone responses
Mean symptom scores during the glucose clamps are shown in Fig. 2. Symptom 
scores in response to clamped hypoglycemia were not different after treatment 
with exenatide compared with treatment with placebo [median change from 
baseline 1.0 (-1.5, 7.0) vs 4.5 (1.5, 5.8), respectively, P = 0.08). 
Treatment with exenatide did not change adrenaline or noradrenaline responses 
to hypoglycemia compared with placebo treatment. GH levels increased in 
response to hypoglycemia after both exenatide and placebo treatment, with no 
between-group differences. There were no differences in cortisol and glucagon 
levels between exenatide and placebo treatment (Fig. 3). 
Appetite scores during clamp
Mean appetite scores were higher during hypoglycemia than after recovery 
from hypoglycemia, both after exenatide treatment (204.0 ± 28.9 vs 130.4 ± 11.3 
mm, P = 0.016) and after placebo treatment (204.5 ± 26.8 vs 120.9 ± 13.5 mm, 
P = 0.004). However, there were no differences between the two treatment 
periods (-73.6 ± 24.8 vs -83.6 ± 21.8 mm, exenatide vs placebo, P = 0.56). 
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Fig. 1. (a) Glucose levels and (b) glucose infusion rates during hyperinsulinemic euglycemic 
hypoglycemic clamps after exenatide treatment (closed circles) and after placebo treatment (open 
circles). GIR, glucose infusion rate; bl, baseline; Hypo, 45 minutes hypoglycemic phase; Rec, 45 





Fig. 2. (a) Autonomic and (b) neuroglycopenic symptom responses to hypoglycemia during 
hyperinsulinemic euglycemic hypoglycemic clamps after exenatide treatment (closed circles) and 
after placebo treatment (open circles). Hypo, 45 minutes hypoglycemic phase; Rec, 45 minutes 
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Fig. 3. Levels of counterregulatory hormones during hyperinsulinemic euglycemic hypoglycemic 
clamps after exenatide treatment (closed circles) and after placebo treatment (open circles). Hypo: 









The main finding of this study is that six weeks treatment with exenatide does 
not improve awareness of hypoglycemia in patients with type 1 diabetes and 
IAH. Although exenatide reduced body weight and BMI, no differences occurred 
in mean blood glucose levels, glucose variability, frequency of hypoglycemic 
events, or symptom scores in response to experimental hypoglycemia between 
exenatide and placebo treatment. Exenatide also did not affect the recovery 
from hypoglycemia.
Our data are largely in agreement with two previous studies examining the 
effect of GLP-1 receptor agonists on responses to hypoglycemia in people with 
type 1 diabetes. Pieber et al. (20) showed that four weeks of treatment with 
liraglutide did not affect symptom or counterregulatory hormone responses 
to hypoglycemia in people with type 1 diabetes and intact awareness of 
hypoglycemia, although glucose infusion rates were lower. Another study 
conducted among patients with poor glycemic control (HbA1c > 8%) reported 
similar results after 12 weeks of treatment with liraglutide 1.2 mg group 
compared with placebo (25). Our study, using a different GLP-1 RA, extends 
these data to patients with IAH.
Previous studies that formed the rationale for the current study showed less 
glucose variability (26,27) and lower frequency of hypoglycemia (26) after 
treatment with the GLP-1RA, liraglutide, in people with type 1 diabetes. In our 
study, however, treatment with exenatide did not affect the rate of or time spent 
in hypoglycemia. This discrepancy may be in part related to the short duration 
of follow-up and the study design. Other studies also found no differences 
in overall hypoglycemia event rate between liraglutide and placebo, using 
treatment periods of 12 or 4 weeks (20,25,27). Patients even seemed to 
experience fewer hypoglycemic events during placebo than during exenatide 
treatment, probably because the double-blind study design necessitated 
adjustment of the insulin doses at fixed time points in both study arms. 
Despite subsequent adjustment based on glucose values, this may still have 
resulted in slightly lower insulin doses than needed in the placebo group and 
slightly higher than needed in the intervention group and may have resulted in 
slightly decreased vs slightly increased risks of hypoglycemia. Both changes 
jeopardize the possibility of identifying a potential positive effect of exenatide 
on symptom scores in response to the hypoglycemic clamp between exenatide 
and placebo treatment. 
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Strengths of our study include the randomized, double-blind placebo-controlled 
study design, the use of CGM, and the use of glucose clamps to measure 
awareness of hypoglycemic symptoms. Our study also has limitations. The data 
should be interpreted in the context of IAH at elevated rate of hypoglycemia, 
which limits generalizability to the broader diabetes population. The number of 
participants in this study, although based on power calculation, was relatively 
low. Although we may have failed to detect more subtle differences between 
treatments, it is unlikely that a larger number of participants would have 
disclosed a clinically relevant benefit of exenatide. By design, we reduced 
insulin doses in both study arms at initiation and titration of study medication, 
which led to a small, albeit nonsignificant, difference in hypoglycemia exposure 
in favor of the placebo study arm. In hindsight , the treatment periods of six 
weeks, chosen because avoidance of hypoglycemia for two to four weeks has 
been shown to reverse the process of impaired awareness of hypoglycemia 
(7,8), may have been too short. A study with longer exposure to study drug is 
needed to disclose whether more extensive use of exenatide may be beneficial 
in the treatment of impaired awareness of hypoglycemia. We found a small 
difference between exenatide and placebo arms in mean glucose levels during 
45 minutes of recovery after hypoglycemia, but this failed to reach statistical 
significance. It  is possible that a longer follow-up period would have resulted in 
a more pronounced separation. 
In conclusion, six weeks treatment with exenatide does not improve awareness 
of hypoglycemia in patients with type 1 diabetes and IAH. Based on the current 
study findings, the adjunctive use of GLP-1RA cannot be recommended for use 
in patients with type 1 diabetes to improve impaired awareness of hypoglycemia. 
Various strategies exist for the management of IAH, including educational 
programs, behavioral therapy, and technological interventions. Despite proven 
effectiveness of several of these approaches (28), however, this condition 
can still be extremely difficult to reverse in daily clinical practice, particularly 
when the patient’s concern about it is low (29).  Future research should focus 
on additional means to sustainably decrease the frequency of hypoglycemic 
events and consequently restore awareness of hypoglycemia in people with 
type 1 diabetes and IAH.   
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Chapter 6 
Effect of short-term use of 
dapagliflozin on impaired awareness 
of hypoglycaemia in people with  
type 1 diabetes
Lian A. van Meijel, Cees J. Tack, Bastiaan E. de Galan




Aims: Impaired awareness of hypoglycaemia (IAH) affects about 25% of 
patients with type 1 diabetes (T1DM). IAH can be reversed by strict avoidance 
of hypoglycaemia for at least 3 weeks. Adjunctive treatment with sodium 
glucose cotransporter 2 inhibitors may reduce the risk of hypoglycaemia 
through reduction of glucose variability. We tested the hypothesis that short-
term use of dapagliflozin may improve awareness of hypoglycaemia in people 
with T1DM and IAH.
Materials and methods: Fifteen patients with T1DM and IAH were included in 
this randomized double-blind, placebo-controlled cross-over trial (age 
49.7±14.6 years, 40% men, disease duration 24.1±14.2 years, HbA1c 7.5± 
0.8% (58.6±8.4 mmol/mol). They were treated with dapagliflozin 10 mg once 
daily or matching placebo, with a washout period of 2 weeks. At the end of 
each treatment period, participants underwent a modified hyperinsulinaemic 
normoglycaemic-hypoglycaemic glucose clamp (glucose nadir 2.5 mmol/L). 
Blinded continuous glucose monitors were used in the final treatment weeks.
Results: Treatment with dapagliflozin significantly improved glycated 
haemoglobin (-0.32±0.10 vs. 0.22±0.13% (-4.1±0.9 vs. 2.3±1.4 mmol/mol), 
dapagliflozin vs. placebo, p=.007) and glucose variability (standard deviation, 
2.6±0.2 vs. 3.1±0.3 mmol/L, p=.029), but did not affect the frequency of 
hypoglycaemia. During the hypoglycaemic clamp, dapagliflozin did not affect 
symptom responses (8.0±3.4 vs. 5.2±1.6, p=.31), but significantly reduced 
the need for exogenous glucose to maintain hypoglycaemia (3.2±0.3 vs. 4.1± 
0.4 mg·kg-1·min-1, p=.022). 
Conclusions: Eight weeks of treatment with dapagliflozin did not restore 
hypoglycaemic awareness in people with T1DM and impaired awareness of 
hypoglycaemia, but ameliorated some clinical aspects.
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Introduction
Iatrogenic hypoglycaemia is the most frequent, acute complication of insulin 
therapy in people with type 1 diabetes. On average, people with type 1 diabetes 
experience 2-3 hypoglycaemic events per week (1, 2) and each year one severe 
hypoglycaemic event (3), defined by appearance of cognitive impairment 
of such a degree that is requires external assistance for recovery (4). Timely 
recognition of (the typical symptoms of) hypoglycaemia is critical to prevent 
severe hypoglycaemia. Recurrent hypoglycaemia can induce a process of 
habituation leading to the syndrome of impaired awareness of hypoglycaemia 
(IAH), which affects about 25% of patients with type 1 diabetes (1, 5). These 
people have lost the capacity to timely detect hypoglycaemia, increasing the 
risk to develop severe hypoglycaemia up to six-fold (6). 
Risk factors for IAH  include a recent history of hypoglycaemia, low C-peptide 
levels and longer diabetes duration (7-9). Marked glucose variability may 
contribute to both the development and persistence of IAH, possibly mediated 
by increased incidence of hypoglycaemia, following or not following (too 
aggressive) corrections of recurrent hyperglycaemia (1, 10). Meticulous 
avoidance of hypoglycaemia for at least 3 weeks has been shown to reverse IAH 
(11, 12). However, the often associated deterioration of glycemic  control [i.e., 
rise of glycated haemoglobin (HbA1c)] is an important limitation of this strategy 
and in daily clinical practice many patients revert back upon retightening of 
glucose control.
Sodium-glucose co transporter 2 (SGLT-2) inhibitors selectively inhibit SGLT-
2 in the proximal tubules of the kidney, leading to decreased reabsorption of 
filtered glucose and an increase in urinary glucose excursion (13, 14). SGLT-
2 inhibitors have been shown to improve glucose control without increasing 
the incidence of hypoglycaemia in people with type 1 diabetes (15, 16). 
Furthermore, time in range (TIR) has been reported to increase during 
treatment with an SGLT-2 inhibitor (17), reflecting reduced glucose variability. 
More stability in day-to-day glucose control may ameliorate awareness 
of hypoglycaemia in patients with IAH, as a result of reduced exposure to 
hypoglycaemia. We therefore hypothesized that SGLT-2 inhibition would be 
helpful in restoring hypoglycaemic awareness in people with IAH. To test this 
hypothesis, we investigated the effect of short-term treatment with the SGLT-
2 inhibitor dapagliflozin on counterregulatory responses to insulin-induced 





This was a randomized, double-blind, placebo-controlled cross-over 
intervention performed at the Radboud University Medical Center (Nijmegen, 
the Netherlands). The study was approved by the local institutional review 
board and performed according to the principles of the Declaration of Helsinki. 
All participants provided written informed consent. 
Study population
Patients with type 1 diabetes were recruited from the outpatient diabetes clinic 
of the Radboud University Medical Center. Patients were included between 
November 2018 and August 2019. Criteria for inclusion were: age 18-75 years, 
type 1 diabetes duration ≥1 year, BMI 19-40 kg/m2, insulin treatment according 
to basal-bolus insulin regimen, HbA1c <9% (75 mmol/mol), and the presence 
of IAH as assessed by a score of ≥3 on the Dutch modified version of the Clarke 
questionnaire (18). Key exclusion criteria were current treatment with or 
known intolerance to SGLT-2 inhibitors, treatment with glucose- or immune-
modifying agents other than insulin, history of cardiovascular disease and/or 
severe kidney failure, diabetes-related complications (except for background 
retinopathy and asymptomatic peripheral neuropathy) and history of diabetic 
ketoacidosis requiring medical intervention within 1 month before screening.
Study procedure
Participants first came for a screening visit, which included medical history and 
standard physical examination (including body weight, height, blood pressure, 
pulse rate and screening for peripheral neuropathy). Blood was sampled for 
determination of HbA1c and serum creatinine.
After inclusion, patients were randomly assigned to treatment with dapagliflozin 
or matching placebo for 8 weeks in a cross-over fashion, with a 2-week 
washout period between treatment periods. Participants were enrolled by the 
investigator and were assigned to dapagliflozin or placebo treatment according 
to a randomization list that was managed by the pharmacy department of our 
hospital, to ensure the double-blinded study design. Randomization was done 
by a computer program with the use of blocks of two subjects, to ensure that 
equal numbers of participants would start treatment with either dapagliflozin or 
placebo. Before start of the study medication, patients received ketone meters 
and were advised about how to identify potential symptoms of (normoglycemic) 
diabetic ketoacidosis (e.g., nausea, vomiting). Patients were instructed to 
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contact the study site in case of (suspected) symptoms of ketoacidosis, and if 
self-measured blood ketone readings were ≥1.5 mmol/L, irrespective of blood 
glucose levels. Dapagliflozin and placebo capsules were dosed 10 milligrams 
once daily. After start of the study medication, patients were instructed to 
reduce prandial insulin levels by 10% to decrease the risk of hypoglycaemia. 
Participants were asked to perform 4-point daily blood glucose profiles and to 
keep a glucose diary for the duration of the study. Insulin doses were adjusted 
according to the glucose profiles, aiming for fasting and pre-meal blood glucose 
levels of 4 to 7 mmol/L without the occurrence of hypoglycaemia. In weeks 1, 2, 
4 and 6, insulin dose adaptations and potential side effects were documented 
by telephone consultation. Patients recorded any hypoglycaemic event in their 
glucose diary, and whether they needed help from someone. During the final 
week of each treatment period, subjects completed 7-point glucose profiles, 
and wore a blinded continuous glucose monitor (CGM) (Dexcom G6; Dexcom 
Inc., San Diego, CA, USA) for at least five days. 
At the end of each treatment period of 8 weeks, subjects underwent a 
hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp (nadir, 2.5 
mmol/L). Participants were asked to come to the clinical research facility after 
an overnight fast, having abstained from alcohol, caffeine and smoking for 24 
hours and from strenuous exercise for 48 hours. Participants were asked to 
reduce the basal insulin dose to avoid hypoglycaemia the day and night before 
the clamp. The clamps were rescheduled in case of hypoglycaemia (glucose 
≤3.0 mmol/L). After arrival at the research facility, one intravenous cannula 
was inserted into the antecubital vein for infusion of insulin and glucose, and 
the other cannula was inserted in a retrograde way in a forearm vein. This 
forearm was placed in a heated box (55ºC) so that arterialized blood could be 
obtained. Glucose levels were determined every 5 minutes using Biosen C-Line 
(EKF Diagnostics, Cardiff, U.K.) (19). Glucose 20% (Baxter B.V., Deerfield, IL) 
and insulin (insulin aspart; Novo Nordisk, Bagsvaerd, Denmark) were infused 
in the contralateral arm. Baseline hyperglycaemia was corrected as needed 
with a small bolus of insulin. Subsequently, a hyperinsulinaemic (60 mU·m-
2·min-1) euglycaemic-hypoglycaemic glucose clamp was initiated. The duration 
of the euglycaemic phase (target glucose, 5.0 mmol/L) was 30 minutes, after 
which glucose levels were allowed to fall to 2.5 mmol/L over ~35 minutes and 
maintained there for another 45 minutes. Blood samples were collected at 
several timepoints (i.e., at baseline, after 30 minutes of euglycaemia, after 20 
and 45 minutes of hypoglycaemia, and after recovery from hypoglycaemia or 
90 minutes after hypoglycaemia if not fully recovered) for the measurement of 
catecholamines, insulin, glucagon, cortisol and growth hormone. Participants 
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were also asked to rate hypoglycaemic symptom scores by a validated 
questionnaire at those timepoints (18). Symptoms were scored from 0 (none) 
to 6 (severe) and divided into autonomic symptoms (e.g. sweating, trembling 
and palpitations), neuroglycopenic symptoms (e.g. confusion, blurred vision 
and difficulty speaking), general symptoms (e.g. nausea and headache) and 
dummy symptoms (pain in the legs and yellow vision) (18, 19). 
At the end of the hypoglycaemic phase, participants were asked to estimate the 
current glucose level, and to eat as much as they thought would be necessary 
to recover from hypoglycaemia. Insulin infusion was stopped at that moment 
and glucose infusion was tapered until stop over 35 minutes. Glucose levels 
were measured until 90 minutes after hypoglycaemia or until glucose levels 
reached ≥8.0 mmol/L. A questionnaire on appetite was administered at 
the abovementioned timepoints during the clamp and after recovery. This 
questionnaire consisted of a visual analogue scale (0-100 mm) on which 
patients rated hunger, fullness, prospective consumption, desire to eat, and 
thirst (maximal score 500 mm) (20).
Study outcomes
The primary study endpoint was the symptom score in response to insulin-
induced hypoglycaemia during the hyperinsulinaemic clamp. A power calculation 
aimed at finding an increase of at least 40% in hypoglycaemia-induced autonomic 
symptom score response with a power of 80% yielded a total number of 
participants of 15, where drop-outs would be replaced. Differences in symptom 
scores were calculated between euglycaemia and the second hypoglycaemic 
timepoint (after 45 minutes of hypoglycaemia). Secondary outcome measures 
included plasma levels of counterregulatory hormones in response to clamped 
hypoglycaemia, maximal glucose excursion after hypoglycaemia, time until 
recovery from hypoglycaemia (defined as a glucose level above 4.0 mmol/L), 
glucose infusion rates during euglycaemia and hypoglycaemia, self-reported 
appetite scores during and after hypoglycaemia, and amount of calories and 
carbohydrates consumed after hypoglycaemia. Other secondary outcomes 
were the change in total daily insulin dose, body weight, and HbA1c, as well 
as mean 24-hour glucose levels, glucose variability  and percentages of time 
spent above-, in- and below range, as derived from CGM downloads. TIR was 
defined as glucose levels between 3.9-10.0 mmol/L, according to predefined 
Dexcom G6-settings and endorsed by a recent consensus statement (21). 
Glucose variability was defined by both the average standard deviation and the 
coefficient of variation of 24-hour glucose levels.
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Measurements 
HbA1c was measured by the TOSOH G8 HPLC-analyser, distributed by Sysmex. 
Plasma adrenaline and noradrenaline were analysed by high-performance 
liquid chromatography combined with fluorometric detection (19). Plasma 
insulin was assessed by an in-house radioimmunoassay (22). Plasma glucagon 
was measured by radioimmunoassay (Eurodiagnostica, Malmö, Sweden). 
Plasma growth hormone and cortisol were determined using a routine analysis 
method with an Electrochemiluminescent Immunoassay on a Modular Analytics 
E170 (Roche Diagnostics, GmbH, Mannheim, Germany). 
Statistical analysis
Data were analysed using IBM SPSS statistics version 25. All data are expressed 
as the mean ± SEM, unless otherwise specified. p-value <.05 was considered 
statistically significant. We tested for normality using the Shapiro-Wilk test 
and QQ plots. Differences in means within groups were analysed using paired 
Student t tests (when normally distributed) and Wilcoxon signed rank tests 
(when not normally distributed). Serial data were analysed by two-way 
repeated-measures ANOVA. 
Results
A total of 15 patients with type 1 diabetes and IAH were included; two 
participants withdrew consent (one because of a wish to become pregnant, 
one because of fear for possible side effects) before start of the study, 
both of whom were replaced. As a result, 15 patients completed the study, 
baseline characteristics are shown in table 1. Results related to the two 
hyperinsulinaemic hypoglycaemic clamps were based on 14 patients because 
one patient only completed one of the two clamps. The patients were generally 
well-controlled and the majority was on an insulin pump. Seven patients were 
on real-time CGM and 3 patients used flash glucose monitoring (FGM).  
Hypoglycaemic glucose clamps 
Before start of the clamp, glucose levels were lower after dapagliflozin than 
after placebo treatment (7.1±0.6 vs. 10.1±0.8 mmol/L, p=.002). During the 
clamp, mean glucose levels for the euglycaemic phase (5.0±0.1 vs. 4.8±0.1 
mmol/L, p=.07) and the hypoglycaemic phase (2.8±0.0 vs. 2.8±0.0 mmol/L, 
p=.84) were similar for dapagliflozin and placebo, respectively (figure 1), 
although nadir plasma glucose levels slightly differed (2.5±0.0 vs. 2.4±0.0 
mmol/L, p=.031). Plasma insulin levels were comparable during both 
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clamps. At baseline, betaχhydroxybutyrate (BHB) levels were higher after 
dapagliflozin than after placebo treatment (0.65 [0.22, 0.92] mmol/L vs. 
0.06 [0.05, 0.37] mmol/L, p=.003), but suppressed to similar extent during 
hypoglycaemia (0.03 [0.03, 0.07] mmol/L vs. 0.03 [0.03, 0.03], p=.18). 
Symptom scores in response to hypoglycaemia did not differ between 
treatment with dapagliflozin and placebo (mean difference from euglycaemia 
8.0±3.4 vs. 5.2±1.6, p=.31) (figure 2).Treatment with dapagliflozin also did 
not alter counterregulatory hormone responses to hypoglycaemia, when 
compared to placebo treatment (figure 3).
Table 1. Baseline characteristics 
n = 15
Age, years 49.7 ± 14.6
Male gender, n (%) 6 (40)
Weight, kg 77.5 ± 13.1
BMI, kg/m² 25.1 ± 3.0
Score on modified Clarke questionnaire 3.0 [3.0, 4.0]
Complications, n (%)
   Retinopathy 0 (0)
   Neuropathy 1 (6.7)
   Nephropathy 0 (0)
Duration of diabetes, years 24.1 ± 14.2
Insulin therapy, n (%)
   CSII 9 (60)
   MDI 6 (40)
Insulin dose, IU/day 42.4 ± 19.4
Insulin dose, IU/kg 0.55 ± 0.2
HbA1c, % (mmol/mol) 7.5 ± 0.8 (58.6 ± 8.4) 
Creatinine, µmol/L 71.9 ± 16.9
Data are presented as number (%), mean±SD or median [IQR]. CSII=continuous subcutaneous 
insulin infusion; MDI= multiple daily injections.
Mean glucose infusion rates (GIR) did not differ between treatments during 
euglycaemia (3.0±0.4 vs. 3.6±0.4 mg·kg-1·min-1, p=.14), but were significantly 
lower with dapagliflozin than with placebo during hypoglycaemia (3.2±0.3 vs. 
4.1±0.4 mg·kg-1·min-1, p=.022) (figure 1). Mean time until glycaemic recovery 
after hypoglycaemia was 17.5±2.1 minutes after dapagliflozin treatment and 
21.8±2.1 minutes after placebo treatment (p=.17). Maximal glucose excursion 
during recovery after 45 minutes of hypoglycaemia was 8.0±0.2 mmol/L 
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after dapagliflozin treatment and 8.0±0.2 mmol/L after placebo treatment 
(p=.96). There were no differences in appetite scores at either time point 
during and amount of carbohydrates and calories consumed after the 
clamp between the two treatments. 
Treatment periods
Compared to placebo, 8 weeks dapagliflozin treatment significantly 
decreased HbA1c (-0.32±0.10 vs. 0.22±0.13% (-4.1±0.9 vs. 2.3±1.4 mmol/mol), 
p=.007). Total daily insulin dose did not change and was not different at the 
end of the two 8-week treatment periods between dapagliflozin and placebo 
(35.9±3.2 vs. 37.1±3.5 IU, p=.28). Compared to placebo, dapagliflozin also 
reduced body weight (-2.3±0.6 vs. -0.1±0.5 kg, p=.033). The median number 
of self-reported hypoglycaemic events per person per week was 0.9 (0.4, 2.4) 
with dapagliflozin and 1.0 (0.3, 1.4) with placebo treatment (p=.70). Two 
episodes of severe hypoglycaemia were recorded, one in each of the treatment 
periods, both in the same participant. 
Fig. 1. (a) Glucose levels and (b) 
glucose infusion rate (GIR) during 
the hyperinsulinaemic clamps after 
treatment with dapagliflozin (closed 
circles) or placebo (open circles). Eu, 
30 min euglycaemic phase; Hypo, 45 
min hypoglycaemic phase; Recovery, 






Mean 24-hour glucose levels during the final dapagliflozin treatment weeks 
were 7.6±0.3 mmol/L and 8.2±0.4 mmol/L with placebo treatment (difference, 
-0.6±0.3 mmol/L, p=.075). Glucose variability reflected by the standard deviation 
of glucose levels was significantly lower during treatment with dapagliflozin as 
compared to placebo (SD, 2.6±0.2 vs. 3.1±0.3 mmol/L, p=.029). The coefficient 
of variation showed a trend towards lower glucose variability during treatment 
with dapagliflozin as compared to placebo (CV, 33.6±0.0 vs. 36.9±0.0 %, p=.07). 
The percentage of time spent in range was not significantly different after both 
treatment periods (72.9±3.3 vs. 68.0±4.2%, p=.19). Although TIR was higher 
in participants already using real-time CGM (or FGM) than in participants who 
did not, dapagliflozin did not further improve TIR in either subgroup when 
compared to placebo. Median percentage of time spent below range (glucose 
<3.0 mmol/L) and mean percentage of time spent above range (glucose>10.0 
mmol/L) also did not differ between treatment periods (0.4 [0.0, 3.7] vs. 1.5 
[0.3, 2.1]%, p=.76 and 20.7±3.3 vs. 26.0±4.1%, p=.15, respectively).  
Fig. 2. (a) Autonomic and (b) neuroglycopenic symptom scores during clamped euglycaemia (white 
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Adverse effects 
One patient had a genital infection during dapagliflozin treatment, treated 
with antimycotic therapy, another had a urinary tract infection during placebo 
treatment, treated with antibiotics. One participant suffered from flu-like 
symptoms for 3 days during dapagliflozin treatment, which were self-limiting. 
Other adverse events included food poisoning, shoulder bursitis and an ankle 
fracture. Diabetic ketoacidosis did not occur during either treatment period. 
Fig. 3. (a-e) Levels of counterregulatory hormones during hyperinsulinaemic clamps after treatment 
with dapagliflozin (closed circles) or placebo (open circles). Hypo, 45 min hypoglycaemic phase; Rec, 









The main finding of this study is that 8 weeks of treatment with dapagliflozin did 
not restore hypoglycaemic awareness in people with type 1 diabetes and IAH, 
but ameliorated one aspect of IAH. Indeed, treatment with dapagliflozin reduced 
the need for exogenous glucose to maintain hypoglycaemia during the clamp, 
reflecting greater endogenous glucose appearance. Dapagliflozin also reduced 
HbA1c and improved glucose variability without increasing the frequency of 
hypoglycaemia or the time spent below the range of normoglycemia. 
This is the first study specifically examining the effect of treatment with an SGLT-
2 inhibitor in people with type 1 diabetes and IAH. Our data of improved glucose 
control and reduced glucose variability are in line with previous studies that 
investigated SGLT-2 inhibitor treatment in people with type 1 diabetes (16, 17, 
23-28). Remarkably, these improvements were achieved against a background 
of already reasonably-well glucose control and – similar to previous studies – 
without increasing the risk of (severe) hypoglycaemic events or the time spent 
in hypoglycaemia (15-17, 23-25). In other words, treatment with dapagliflozin 
shifted the inverse relationship between HbA1c and incidence of hypoglycaemia 
to the left, but contrary to our aims, this effect was entirely due to a change in 
the first rather than the second component. 
Symptom scores in response to clamped hypoglycaemia were numerically 
higher after dapagliflozin treatment when compared to placebo, but this 
difference was not statistically significant. Dapagliflozin treatment was 
associated with a reduced GIR during the hypoglycaemic condition of the 
clamp, reflecting lower external glucose requirements and consequently 
greater endogenous glucose rising capacity to maintain the same blood glucose 
level. Since no single counterregulatory hormone response was enhanced by 
dapagliflozin, this effect may be due to the composite glucose-increasing effect 
of all counterregulatory hormones combined or to increased beta-adrenergic 
sensitivity, a reduction of which has been demonstrated in people with IAH 
(29, 30). Given the mechanism of action of SGLT2 inhibitors, we would have 
expected higher glucagon levels in the dapagliflozin arm. We have not been able 
to show such increases in glucagon in patients with type 1 diabetes treated with 
SGLT-2 inhibitors. This may perhaps be due to glucagon levels being already 
somewhat elevated due to loss of the inhibitory effect of endogenous insulin 
secretion. Beta‐hydroxybutyrate levels before start of the clamps were higher 
after dapagliflozin than after placebo treatment. However, although ketones 
115
Effect of dapagliflozin on impaired awareness of hypoglycemia in type 1 diabetes
6
may be used as an alternative for glucose, these levels were almost completely 
suppressed during hypoglycaemia, thus unlikely to explain the differences in 
glucose requirements. 
Apart from reduced need for exogenous glucose to maintain hypoglycaemia, 
treatment with dapagliflozin was not better than placebo in enhancing 
counterregulatory hormone responses to or symptomatic awareness of 
hypoglycaemia during the clamp. The most obvious explanation for these results 
is that dapagliflozin did not affect hypoglycaemia event rates, presumably 
because the participants were more concerned about (reducing) hyper- 
than hypoglycaemic excursions (31). Although this study cannot claim clear 
beneficial effects of dapagliflozin on IAH, there are several points to consider. 
First, the frequency of hypoglycaemia in our study was around one episode 
per week, which is already low for people with type 1 diabetes in general, let 
alone for a population with IAH. The proportion of time spent below range was 
similarly low, averaging 0.4 and 1.5% for dapagliflozin and placebo treatment, 
respectively. Second, the TIR of around 70% in both study-arms was much higher 
than observed in other studies on SGLT-2 inhibitor treatment (17, 23, 24, 26-
28) and close to or above the target recommended by current guidelines (21). 
Both points suggest that optimal treatment was already achieved in the placebo 
arm in terms of avoiding hypoglycaemia without deteriorating overall glucose 
control, perhaps due to study instructions to intensify glucose monitoring, 
with or without CGM. Indeed, about a third of the participants had retained 
sufficient awareness after both treatments to correctly identify the second part 
of the clamp as being hypoglycaemic. Although speculative, we would posit 
that this effect may have reduced our participants’ interests in further avoiding 
hypoglycaemia to improve awareness, but rather use dapagliflozin to limit the 
occurrence of hyperglycaemic events, thus improving overall glucose control 
without increasing this risk.
Impaired awareness of hypoglycaemia is a complex clinical syndrome that 
is difficult to reverse. Although various agents and interventions have been 
shown to enhance counterregulatory responses to hypoglycaemia (32-35), 
few have been tried in longer-term studies and none were effective in restoring 
hypoglycaemic awareness. This includes CGM, although its use effectively 
reduces the risk of severe hypoglycaemia as the main consequence of IAH (36). 
One explanation for the failure to resolve IAH may relate to many people with 
IAH being more concerned about hyperglycaemia and associated complications 
and prone to underestimating the risks of hypoglycaemia (31, 37). Use of 
SGLT-2 inhibitors may play a role in improving IAH, although its use should be 
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carefully balanced against the risk of diabetic ketoacidosis (38). We did not 
observe any episode of ketoacidosis in our trial, but the risk of ketoacidosis 
remains a controversial issue when it comes to approving treatment with SGLT-
2 inhibitors for patients with type 1 diabetes (39, 40). 
Strengths of our study include the study design (randomized, double-blind 
and placebo-controlled), the use of glucose clamps to measure awareness of 
hypoglycaemia and the use of (blinded) CGMs. Our study also has limitations. 
First, we did not perform glucose clamps at baseline to measure hypoglycaemic 
symptom scores. This would have increased the study burden to participants. 
The duration of the study was relatively short when compared to other studies. 
However, 3 weeks of hypoglycaemia avoidance is reportedly sufficient to 
improve hypoglycaemic awareness (11, 12) and we showed meaningful results 
with respect to glucose variability and HbA1c, so that a longer study duration is 
unlikely to have produced different results. The cross-over design may have 
influenced the results by carry-over effects, despite the 2-week washout period 
between the treatment periods. This study design was chosen because the high 
statistical power allowing substantially fewer study participants than parallel 
designed studies, particularly given the intensity of the interventions scheduled 
(particularly hypoglycaemic clamps). Cross-over studies generally result in 
more homogeneous study populations. Moreover, we used block randomization 
to minimize the impact of carry-over effects, which was not found by formal 
testing. 
In conclusion, 8 weeks of treatment with dapagliflozin did not restore 
hypoglycaemic awareness in people with type 1 diabetes and IAH, but 
ameliorated one aspect of IAH. Treatment with dapagliflozin lowered HbA1c 
without increasing the risk of hypoglycaemia, and decreased glucose variability 
in people with type 1 diabetes and IAH. In theory this should result in less time 
in hypoglycaemia when aiming at a stable HbA1c, but larger studies, including 
more subjects with and without CSII and CGM, are needed to determine the 
exact value of adding SGLT-2 inhibitors on hypoglycaemia awareness. 
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The aim of this thesis was to provide further insight in the pathophysiology 
and prevalence of impaired awareness of hypoglycemia (IAH) in people with 
diabetes, and to explore potential treatment options to improve awareness of 
hypoglycemia in patients with IAH. Despite almost a century of innovations in 
insulin therapy and glucose monitoring, still only a minority of patients with 
type 1 diabetes and those with advanced type 2 diabetes are able to achieve 
widely recommended glucose targets. As a result, many suffer from or remain 
at increased risk of micro- and macrovascular complications. Iatrogenic 
hypoglycemia is the most common adverse event of insulin treatment, the 
cause of considerable morbidity and mortality, and the principal barrier for 
optimizing glucose control, particularly in those with the clinical syndrome of 
IAH. Eliminating hypoglycemia from the lives of people with diabetes will not 
only improve quality of life and clinical outcomes directly, but will also enable 
achieving true normoglycemia for endurable periods of time, thus considerably 
ameliorating the risk of vascular complications. Better understanding of 
hypoglycemia and IAH, and investigation of potential treatment options for IAH 
therefore remains imperative.
IAH is characterized by blunted counterregulatory hormone responses to and 
reduced symptomatic perception of hypoglycemia. Usually, IAH results from 
a process of habituation to recurrent hypoglycemia, yet the exact underlying 
mechanisms are still not fully understood. Recent studies suggest involvement 
of both adaptations in brain lactate handling and alterations in cerebral blood 
flow (CBF). We examined the link between these two factors by investigating the 
effect of lactate administration on CBF during insulin-induced hypoglycemia. 
To do so, we exposed people with type 1 diabetes and normal awareness of 
hypoglycemia (NAH) to experimental hypoglycemia during either lactate or 
placebo infusion, while measuring both global and regional CBF, using pseudo-
continuous arterial spin labeling (ASL) MRI. As described in chapter 2, global 
CBF significantly increased in response to intravenous lactate infusion, as 
compared to placebo infusion. Also, lactate infusion significantly suppressed 
counterregulatory hormone responses to hypoglycemia, although it did not 
alter symptom score responses. These results further confirm that lactate 
administration is able to mimic – at least – the suppressed hormonal component 
of IAH. This effect is usually attributed to oxidation of lactate as alternative 
energy source. However, our data show that part of this effect may be due to the 
increase in global CBF, resulting in increased supply of nutrients to the brain 
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to maintain brain metabolism, which in turn suppresses counterregulatory 
hormone responses to hypoglycemia.  
The prevalence of impaired awareness of hypoglycemia has been well described 
in people with type 1 diabetes and affects 25-30% of the population. Less is 
known about the prevalence of IAH in people with type 2 diabetes on insulin 
therapy. Studies that have been performed on this topic are typically small 
(single-center) and show a high level of variation. In the nationwide Dutch 
Diabetes Pearl cohort, a total of 2350 people with type 2 diabetes on insulin had 
been asked to complete a validated questionnaire on hypoglycemic awareness. 
In chapter 3, we report the prevalence and determinants of IAH and of self-
reported severe hypoglycemia based on the results of this questionnaire. We 
found that almost 10% of insulin-treated type 2 diabetes patients could be 
classified as having IAH, and almost a third reported to have experienced a 
severe hypoglycemia in the past year. People on complex basal-bolus insulin 
regimens or on premixed insulin were at higher risks for both IAH and severe 
hypoglycemia, but IAH and severe hypoglycemia definitively also occurred in 
people on basal insulin alone. IAH was also more prevalent in people without 
a partner or a BMI<30 kg/m2, whereas severe hypoglycemia was reported more 
often in people with non-Caucasian ethnicity or using psychoactive drugs. This 
study shows that IAH and particularly severe hypoglycemia are common in 
people with type 2 diabetes on insulin therapy, emphasizing the importance of 
greater awareness for IAH and severe hypoglycemia in these people.
Achieving normoglycemia with the correctly calculated insulin dose around meals 
while avoiding hypoglycemia remains challenging for people with diabetes on 
intensive insulin regimens. Patients are usually advised to estimate the amount 
of prandial insulin needed taking into account several factors, including current 
and target blood glucose levels, carbohydrate content, insulin-to-carbohydrate 
ratio (ICR) and insulin sensitivity. Optimal insulin dosing can be supported by 
bolus calculation tools, which are highly advocated. However, whether such 
tools offer benefit for people with type 1 diabetes on long-term insulin pump 
therapy had not been investigated. This group of patients had often started 
pump therapy before bolus calculation tools existed. In chapter 4, we describe 
the results of an open-label parallel prospective study to investigate the effect 
of 4 months use of automated bolus calculation on glucose variability in patients 
with type 1 diabetes on insulin pump therapy. These patients were relatively 
well controlled and on insulin pump therapy for several years. Automated bolus 
calculation resulted in significant improvement in glucose variability, but there 
was no improvement in glucose control, incidence of hypoglycemia or quality 
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of life. There was also no improvement in level of hypoglycemic awareness in 
those with IAH. Automated bolus calculation may therefore fit in a personalized 
treatment strategy for patients on insulin pump therapy, but only with sufficient 
motivation and knowledge to use this tool. 
As discussed above, IAH results from habituation to recurrent hypoglycemia. 
This functional defect can be reversed by strict avoidance of hypoglycemic 
events for 2-4 weeks. We reasoned that marked glucose variability could 
contribute to the development and persistence of IAH because of too aggressive 
corrections of hyperglycemic events, leading to recurrent hypoglycemia. 
Conversely, it could be posited that improvement in glucose variability 
would lead to improvement in IAH by reducing the burden of both hyper- and 
hypoglycemia. Both glucagon-like-peptide-1 (GLP-1) receptor agonists 
and sodium glucose cotransporter 2 (SGLT-2) inhibitors have been shown to 
improve glycemic control without increasing the risk of hypoglycemia and are 
advocated for the treatment of type 2 diabetes because of their cardioprotective 
effects. Although their mechanisms differ, both these agents are known to 
decrease glucose variability predominantly by reducing postprandial glucose 
excursions, not only in people with type 2 diabetes, but also in those with type 
1 diabetes.  We therefore conducted two double-blind, placebo-controlled, 
cross-over studies to investigate the effect of treatment with the GLP-1 receptor 
agonist, exenatide, and with the SGLT-2 inhibitor, dapagliflozin, on impaired 
awareness of hypoglycemia in people with type 1 diabetes (chapters 5 and 6). 
In both studies, glucose levels were continuously monitored using a glucose 
sensor in the final week and a hyperinsulinemic hypoglycemic glucose clamp 
was conducted on the last day to rigorously assess awareness of hypoglycemia.
In the first study (described in chapter 5), participants were randomized to 
six weeks of treatment with exenatide or matching placebo, followed by the 
alternative treatment after 4 weeks of wash-out. Treatment with exenatide as 
compared to placebo significantly reduced body weight and BMI, but did not 
affect glucose variability or the frequency of hypoglycemic events. Consequently, 
exenatide did neither improve awareness  nor increase the hormonal responses 
to hypoglycemia, as assessed by experimental, standardized hypoglycemia 
using the clamp. 
In the second study (chapter 6), we randomized participants to eight weeks 
of treatment with dapagliflozin followed by placebo or in the reverse order, 
interspersed with two weeks of wash-out. Treatment with dapagliflozin 
significantly decreased glucose variability and reduced HbA1c levels when 
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compared to placebo treatment without increasing the incidence of hypoglycemia. 
Glucose sensor data showed that the time spent in normoglycemic range 
(glucose between 3.9-10.0 mmol/l) was high and that time spent below range 
was very low during both treatments, without a significant difference between 
the treatment periods. During the hypoglycemic clamp, dapagliflozin reduced 
the need for exogenous glucose to maintain hypoglycemia, reflecting greater 
endogenous glucose appearance, and tended to increase the symptomatic 
response to hypoglycemia numerically. This study shows that treatment with 
dapagliflozin may improve some components of IAH, but does not reverse it 
in patients with type 1 diabetes and IAH, although it improved glucose control 




The results described in this thesis show that (severe) hypoglycemia and 
impaired awareness of hypoglycemia are common problems, not only in 
patients with type 1 diabetes, but certainly also in patients with type 2 diabetes 
on insulin therapy. The reported prevalence of IAH in type 1 diabetes has been 
estimated around 25-30%. In this thesis, we showed that the prevalence of IAH 
in type 2 diabetes patients on insulin therapy is around 10%, and almost a third 
of patients reportedly experienced severe hypoglycemia in the previous year. 
In people with type 1 diabetes, the incidence of IAH has not changed over the 
last 2-3 decades, despite the introduction of insulin analogues and improved 
insulin delivery systems, and there is no reason to suggest that this will be any 
different in people with type 2 diabetes. In fact, the prevalence is expected to 
increase in the latter, given the improvement in overall survival and the greater 
proportion of patients requiring (complex regimens of) insulin treatment. 
Therefore, treatment strategies that effectively improve IAH are urgently 
needed.
IAH is usually the result of an adaptive process induced by recurrent 
hypoglycemic events. Although the mechanisms underlying this process still 
need to be fully uncovered, brain lactate is likely involved in its development. 
Our studies provide further evidence about the role of brain lactate in the 
pathophysiology of IAH by showing its pluriform effect in the brain, i.e. as a non-
glucose alternative fuel and by stimulating brain perfusion that enhances the 
delivery of energy nutrients. 
In clinical practice, it is known that the process of habituation to hypoglycemia 
can be reversed when hypoglycemic events are avoided (1-3). Marked glucose 
variability may play a role in maintaining a higher burden of hypoglycemia (4, 5), 
when it results from frequent overcorrections of hyperglycemic events. We thus 
hypothesized that a decrease in hypoglycemic events following more stability 
in glucose profiles would result in improvement of IAH. In this thesis, we used 
three different strategies to explore the effect of reducing glucose variability 
on IAH in people with type 1 diabetes.
We first tested this hypothesis by examining the effect of automated bolus 
calculation in people with type 1 diabetes who were (reasonably) well-
controlled on insulin pump therapy. Previous studies had shown that 
automated bolus calculation could improve HbA1c without increasing the risk 
of hypoglycemia in people with (relatively) poor glucose control or naïve to 
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insulin pump therapy (6, 7). Since glucose control was already relatively good 
in our study population, the aim was to reduce the incidence of hypoglycemia 
and improve glucose variability. We indeed showed that 4 months use of bolus 
calculation resulted in some improvement of glucose variability, but there 
were no differences in frequency of hypoglycemic events nor in awareness 
of hypoglycemia. This may be due to the fact that the majority of patients 
enrolled were highly experienced in insulin pump therapy and probably 
already performed the calculations ‘routinely’, thus limiting the added value of 
the bolus calculator. Also, calculating the optimal insulin bolus involves more 
than carb counting and glucose metrics. However, patients who start with 
insulin pump therapy may still experience beneficial effects of automated bolus 
calculation, as will those with high HbA1c values motivated to improve glucose 
control. In these situations, automated bolus calculation probably remains a 
valuable tool in addition to insulin therapy. 
Two other potential ways to improve glucose variability and reduce the 
hypoglycemic burden that we investigated, concerned pharmacological 
interventions. GLP-1 receptor agonists have been shown to delay gastric 
emptying, reduce postprandial hyperglycemia and improve glucose variability, 
effects that have also been demonstrated in type 1 diabetes (8, 9). For instance, 
treatment with liraglutide in patients with type 1 diabetes resulted in less 
glucose variability and lower HbA1c than treatment with placebo, without 
increasing the risk of hypoglycemia (10-12). With our study, our goal was 
to improve hypoglycemic awareness through reduction of the incidence of 
hypoglycemia without worsening overall glucose control. However, six weeks 
of treatment with exenatide on top of existing insulin treatment did not reduce 
the frequency or improve awareness of hypoglycemia or affect any other 
parameter of glucose control in patients with type 1 diabetes and IAH. These 
somewhat disappointing results extend those from various other studies 
showing no effect of GLP-1 receptor agonists on the frequency of hypoglycemia, 
time spent in hypoglycemia (11, 13, 14) or counterregulatory hormone or 
symptom responses to clamped hypoglycemia (13, 14), in type 1 diabetes 
patients who did not have IAH. However, since our study was relatively short, 
particularly as the first two weeks were used for up-titration of the treatment, 
we cannot completely exclude that longer duration of treatment with a GLP-1 
receptor agonist may be beneficial. 
In the subsequent study with the SGLT-2 inhibitor, dapagliflozin, we extended 
the treatment period to 8 weeks. Treatment with SGLT-2 inhibitors has been 
shown to reduce HbA1c and glucose variability without increasing the incidence 
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of hypoglycemia in people with suboptimally controlled type 1 diabetes (15). 
As discussed above, we reasoned that lower glucose variability could benefit 
patients with IAH, when it would result in fewer hypoglycemic events. The 
results of the study were mixed. Dapagliflozin treatment indeed decreased 
glucose variability, but rather than reducing the incidence of hypoglycemia, it 
further improved already good glycemic control (lower HbA1c). It furthermore 
reduced the need for exogenous glucose to maintain hypoglycemia during the 
clamp, reflecting greater endogenous glucose production. However, there 
were no differences in counterregulatory hormone responses to hypoglycemia 
and symptomatic awareness of hypoglycemia. The subjectivity of measuring 
symptom scores by questionnaires versus the more objective way of laboratory 
measuring of blood hormone levels should be acknowledged. Also, hypoglycemia 
elicited symptoms after both treatment periods, possibly resulting from the 
similarly low percentages of time spent in hypoglycemia and suggesting that 
participants were highly motivated to avoid hypoglycemia. Indeed, it should be 
noted that time spent in normoglycemic range was (nearly) 70% during both 
treatments, which is the recommended target according to an international 
CGM consensus guideline, but usually not achievable without real-time glucose 
sensor therapy (16). Thus, it is possible that the participants used the treatment 
to further improve their already good glucose control, being less or no longer 
concerned about the number of hypoglycemic events than would be expected 
from a neutral perspective (17). 
Strategies to improve IAH and avoid (severe) hypoglycemia often deteriorate 
glycemic control, which in daily practice appears not feasible for many people 
with type 1 diabetes mellitus, who are focused on reaching HbA1c even below 
target values, to prevent hyperglycemia-associated development of micro- 
and macrovascular complications. In some patients there seems to be a lack of 
concern about hypoglycemia and its consequences. This may be a barrier to a 
person’s ability or willingness to reduce the incidence of (severe) hypoglycemia 
and improve IAH (17, 18). People with IAH are often more concerned 
about hyperglycemia and associated (micro-) vascular complications than 
patients with NAH (19). People with a lack of concern about hypoglycemia in 
combination with a fear of hyperglycemia may not be able to gain sufficient 
benefit from interventions that aim to reduce the rate of hypoglycemia and 
improve IAH, including continuous glucose monitoring (CGM) devices. Treatment 
of these patients should therefore preferably also focus on such cognitions 
and patients’ knowledge about risks of hypoglycemia and hyperglycemia. A 
combination of pharmacological interventions to reduce glucose variability 
and frequency of hypoglycemia (e.g. with SGLT-2 inhibitors) and cognitive 
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behavioral therapy might be useful in these patients. Altogether, treatment 
of patients with type 1 diabetes and IAH should be based on personalized 
strategies to reduce glucose variability and frequency of hypoglycemia, 
combining pharmacological, educational and technological interventions 
(CGM, automated bolus calculators).
To what extent CGM technology will be able to resolve the problem of IAH 
remains to be seen. In unselected groups of people with (predominantly type 
1) diabetes, both flash glucose monitoring (FGM) and real-time CGM have 
been shown to improve overall glucose control and reduce the incidence of 
hypoglycemic events (ref). Similarly, in those with IAH, use of real-time CGM 
was associated with about halving of the risk of severe hypoglycemic events 
and of time spent below the normoglycemic range. However, despite this 
reduction in exposure to hypoglycemia, the state of awareness of hypoglycemia 
did not improve (20-22). It seems plausible that the lack of CGM to improve 
awareness of hypoglycemia is related to inappropriate cognitions about 
hypoglycemia, as discussed above (17), that technology alone is unable to 
amend. Although studies on FGM have not been performed in patients with IAH 
(23), these devices are not expected to improve awareness of hypoglycemia. 
Since they do not have an alarm function to alert patients when glucose levels 
are low, their effectiveness in hypoglycemia prevention depends heavily on the 
frequency of scanning and the patient’s effort and willingness to do so. Thus, 
despite the development of technological devices that allow for continuous 
monitoring of glucose levels and – in case of real-time CGM – alarm patients 
when hypoglycemia occurs, IAH is expected to remain a problem for a sizeable 
group of people with diabetes. 
Although treatment with SGLT-2 inhibitors in people with type 1 diabetes 
seems promising, these agents are currently only approved by the European 
Medicines Agency (EMA) for use in patients with type 1 diabetes and a BMI>27 
kg/m2. The U.S. Food & Drug Administration (FDA) has not (yet) approved 
SGLT-2 inhibitors for people with type 1 diabetes, because of the increased 
risk of (normoglycemic) diabetic ketoacidosis (DKA) associated with its use 
particularly in people with type 1 diabetes. Most previous studies with SGLT-
2 inhibitors in patients with type 1 diabetes showing improvement in glycemic 
control without increasing the risk of hypoglycemia used a treatment duration 
between 18-52 weeks (15, 24-27). None of these studies investigated the effect 
of SGLT-2 inhibitor use in patients with IAH. In contrast to a number of previous 
studies, no events of diabetic ketoacidosis occurred in our study. We educated 
patients about potential symptoms of DKA and the fact that this can also occur 
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with normal glucose levels. We also provided study participants with ketone 
meters to measure ketone levels at home when they experienced potential 
symptoms of DKA, and they were instructed to contact the hospital when 
ketone levels were elevated. These aspects are key to mitigate the elevated risk 
to develop DKA. Future studies should also focus on potential risk factors to 
develop DKA, such as low baseline HbA1c and inappropriate reductions in basal 
insulin dose of more than 20% when starting SGLT-2 inhibitors. When these 
measures are taken, we believe our study shows promising results regarding 
improvement of glucose variability and improvement of some components of 
the syndrome of impaired awareness of hypoglycemia. 
In conclusion, despite several improvements in diabetes care, (severe) 
hypoglycemia remains a significant problem in patients with diabetes on insulin 
therapy. Consequently, IAH is a common problem in people with type 1 diabetes 
and type 2 diabetes on insulin therapy. We showed several strategies to 
possibly reduce the frequency of hypoglycemia and thereby improve awareness 
of hypoglycemia. Future studies may focus on the combination of treatment 
with SGLT-2 inhibitors and cognitive behavioral therapy, to maximize the effect 
of treatment and to ensure that patients don’t ‘misuse’ medication for further 
lowering of HbA1c instead of improving their awareness of hypoglycemia. 
Reducing the burden and the consequences of, particularly severe, potentially 
hazardous, hypoglycemia, remains an unmet medical need that will improve the 
lives of people with diabetes in many ways.
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Diabetes mellitus, ook wel suikerziekte genoemd, is een ziekte die wereldwijd 
veel voorkomt. Het wordt gekenmerkt door verhoogde bloedsuiker (glucose) 
waarden in het bloed. De ziekte kan onderverdeeld worden in verschillende 
typen, waarvan type 1 en type 2 diabetes mellitus het meest voorkomend zijn. 
Het aantal mensen met diabetes neemt steeds verder toe, zowel in Europa als 
wereldwijd. Langdurig verhoogde glucosewaarden leiden tot beschadiging aan 
verschillende organen in het lichaam; de ogen, de nieren, zenuwen, het hart 
en de bloedvaten. Patiënten ervaren een hoge ziektelast als gevolg van deze 
complicaties. Het beïnvloedt de kwaliteit van leven van patiënten en zorgt zelfs 
voor een verminderde levensverwachting. Het doel van de behandeling van 
patiënten met diabetes is gericht op het normaliseren van de glucosewaarden 
en daarmee het verminderen van het risico op complicaties. 
Insuline wordt geproduceerd door cellen in de alvleesklier. Insuline zorgt 
ervoor dat glucose uit de bloedbaan wordt opgenomen en aan weefsels wordt 
afgegeven als brandstof. Type 1 diabetes wordt gekenmerkt door een auto-
immuun reactie tegen de insuline producerende cellen. Dat wil zeggen dat het 
afweersysteem van het lichaam de eigen cellen aanvalt. Hierdoor is er geen 
insuline productie en zijn glucosewaarden te hoog. Bij type 2 diabetes zijn de 
cellen van weefsels minder gevoelig voor insuline, en is er een relatief tekort 
aan insuline in het lichaam. Dit heeft vaak met overgewicht te maken. Patiënten 
met type 2 diabetes kunnen meestal behandeld worden met tabletten, deze 
verbeteren bijvoorbeeld de gevoeligheid van weefsels voor insuline. Indien 
deze tabletten niet goed genoeg werken moeten patiënten met type 2 diabetes 
insuline spuiten. Patiënten met type 1 diabetes spuiten altijd insuline. 
Een van de meest voorkomende bijwerkingen van insuline spuiten is het 
ontwikkelen van een lage glucosewaarde, ook wel hypoglykemie of hypo 
genoemd. Klachten die patiënten kunnen ervaren bij een hypoglykemie zijn 
onder andere vermoeidheid, trillingen, duizeligheid, hartkloppingen en honger. 
Dit zijn waarschuwingssignalen van het lichaam om te laten weten dat de 
glucosewaarde aan het dalen is en dat patiënten iets moeten eten of drinken 
om de glucosewaarde te laten stijgen. Bij 25% van de patiënten met type 1 
diabetes werkt dit mechanisme echter niet meer goed. Dit betekent dat zij 
pas op een later moment klachten ervaren van een hypoglykemie, wanneer 
de glucosewaarde veel lager is. Dit kan leiden tot gevaarlijke situaties met 




mechanisme wordt ook wel ‘impaired awareness of hypoglycemia’, of afgekort 
IAH, genoemd. IAH ontstaat door gewenning aan lage glucosewaarden. Mensen 
die vaak hypo’s hebben, hebben dus een groter risico op het ontwikkelen 
van IAH. 
Het ontwikkelen van IAH is een omkeerbaar proces. Indien patiënten gedurende 
een aantal weken voorkomen dat ze hypo’s hebben, komt het gevoel voor hypo’s 
weer terug. Dit betekent in de praktijk vaak dat de gemiddelde glucosewaarde 
hoger is, en dat geeft weer meer risico’s op complicaties op de lange termijn. 
Het is dus lastig om hier een goede middenweg in te vinden. 
De afgelopen decennia zijn verschillende onderzoeken gedaan naar andere 
mogelijkheden om het aanvoelen van hypo’s te verbeteren. Een van de nieuwere 
ontwikkelingen is het gebruik van een continue glucose sensor. Deze sensor 
meet continu de glucosewaarde en geeft een alarm aan de patiënt indien de 
glucosewaarde te hoog of te laag is. Door deze alarmering reageren patiënten 
sneller op een afwijkende glucosewaarde en worden hoge of lage uitschieters 
voorkomen. Deze alarmering is met name belangrijk voor patiënten met IAH, 
die hun hypoglykemieën dus niet aan voelen komen. Er zijn ook onderzoeken 
gedaan naar het effect van medicijnen op het verbeteren van IAH. Sommige 
onderzoeken hebben een positief effect laten zien, echter dit zijn vaak kleinere 
patiënten aantallen en een korte of eenmalige behandeling. Dat maakt dat deze 
medicijnen in de dagelijkse praktijk (nog) niet gebruikt worden bij patiënten 
met type 1 diabetes en IAH. Er blijft dus een vraag naar nieuwe onderzoeken die 
laten zien of medicijnen IAH kunnen verbeteren. 
In dit proefschrift onderzochten we hoe het aanvoelen van hypoglykemieën 
verbeterd kan worden bij patiënten met type 1 diabetes. We hebben daarbij 
gekeken of technologie en bepaalde medicijnen een verbetering geven. 
Daarnaast hebben we onderzocht hoe vaak IAH voorkomt bij patiënten met type 
2 diabetes. Tenslotte hebben we onderzocht welk proces ten grondslag ligt aan 
het ontstaan van IAH. 
In hoofdstuk 1 wordt uitleg gegeven over het ziektebeeld diabetes mellitus en 
de achtergrond van IAH. 
Normaal gezien worden in het lichaam verschillende hormonen geproduceerd 
wanneer de glucosewaarde laag is. Deze zorgen ervoor dat het glucose gehalte 
gaat stijgen, of dat patiënten symptomen ervaren die kunnen passen bij een 
140
Chapter 8
hypo. Bij patiënten met IAH is er sprake van een verminderde of afwezige 
productie van deze hormonen. IAH ontstaat door gewenning van het lichaam 
aan eerdere hypoglykemieën. Het exacte onderliggende mechanisme is niet 
bekend. Eerder onderzoek liet zien dat een aanpassing in de verwerking van 
lactaat (melkzuur) in de hersenen hier mogelijk een rol in speelt, samen met 
aanpassingen in de bloeddoorstroming in de hersenen. We onderzochten 
daarom wat het effect van lactaat toediening was op de bloeddoorstroming in 
de hersenen tijdens een hypo. We hebben patiënten met type 1 diabetes die hun 
hypo’s goed aan voelden komen (normal awareness of hypoglycemia, NAH) 
in een experimentele situatie een hypoglykemie laten ondergaan (glucose 
clamp), en daarbij lactaat en placebo (een niet-werkzame stof) toegediend. 
Daarbij hebben we gekeken wat het effect was op de bloeddoorstroming in de 
hersenen met behulp van een MRI-scan. In hoofdstuk 2 staat beschreven dat de 
globale bloeddoorstroming in de hersenen groter was tijdens lactaat toediening 
in vergelijking met placebo. Lactaat zorgde er ook voor dat de hormoonreactie 
op een hypo in het lichaam onderdrukt werd. Er werd geen verschil gezien in de 
symptomen die de patiënten voelden tijdens een hypo. Dit onderzoek laat zien 
dat lactaat een onderdrukte hormoon reactie kan veroorzaken tijdens een hypo, 
zoals gezien wordt bij patiënten met IAH. De hersenen gebruiken lactaat dan 
mogelijk als alternatieve brandstof als glucosewaarden in het bloed laag zijn. 
Daarnaast zorgt lactaat voor een stijging in de globale bloeddoorstroming en 
daardoor voor voldoende aanvoer van voedingsstoffen naar de hersenen tijdens 
een hypo, dit kan ook verklaren waarom een onderdrukking van de hormoon 
reactie en het niet optreden van symptomen tijdens hypo wordt gezien. 
Het voorkomen van IAH bij mensen met diabetes is met name onderzocht bij 
patiënten met type 1 diabetes. De prevalentie hiervan bedraagt ongeveer 
25-30%. Patiënten met type 2 diabetes die insuline gebruiken kunnen ook 
IAH ontwikkelen. Hier is echter minder onderzoek naar gedaan. In Nederland 
bestaat een landelijk cohort met daarin gegevens van patiënten met type 2 
diabetes uit verschillende ziekenhuizen in het land, dit heet het Parelsnoer 
Instituut. Aan 2350 patiënten met type 2 diabetes die insuline gebruiken werd 
gevraagd een vragenlijst over onder andere IAH in te vullen. In hoofdstuk 3 
beschreven we de resultaten hiervan. IAH kwam voor bij ongeveer 10% van 
de patiënten met type 2 diabetes die insuline gebruiken. Meer dan 30% van de 
patiënten had een ernstige hypo in het voorafgaande jaar, dat betekent dat er 
hulp van iemand anders nodig is om te herstellen van een hypo. Er waren een 
aantal risicofactoren voor het ontwikkelen van IAH. Patiënten met een complex 




partner, en patiënten met een BMI onder de 30 hadden een hoger risico op het 
ontwikkelen van IAH. Het risico op een ernstige hypo was hoger bij patiënten 
met complexe insuline schema’s, patiënten van niet-Kaukasische komaf, en 
patiënten die bepaalde medicijnen gebruikten (antipsychotica). Ons onderzoek 
liet dus zien dat IAH en ernstige hypo’s zeker ook voorkomen bij patiënten met 
type 2 diabetes en insuline gebruik.
Het gebruik van insuline bij patiënten met diabetes is geen gemakkelijke 
opgave. Er zijn verschillende factoren waarmee rekening dient te worden 
gehouden. Zo is het bijvoorbeeld van belang om te rekenen hoeveel 
koolhydraten een maaltijd bevat. Daarnaast moet rekening worden gehouden 
met de glucosewaarde op het moment van eten, en de hoeveelheid insuline die 
nodig is om te voorkomen dat de glucosewaarde erg gaat stijgen na het eten van 
de maaltijd. Dit alles maakt dat patiënten makkelijk teveel of te weinig insuline 
gebruiken, en daardoor een te lage of te hoge glucosewaarde krijgen. De bolus 
calculator is een digitale tool die hierin kan helpen. In deze calculator kunnen 
patiënten een aantal gegevens invullen; de hoeveelheid koolhydraten van een 
maaltijd, de hoeveelheid insuline die nodig is om koolhydraten te verwerken, 
de huidige glucosewaarde en de streef glucosewaarde, en de mate van daling 
van glucosewaarde door 1 eenheid insuline. De bolus calculator berekend aan 
de hand van deze getallen de hoeveelheid insuline die nodig is om de maaltijd 
te verwerken, om te voorkomen dat een te hoge of te lage glucosewaarde 
ontstaat. Als glucosewaarden in het bloed erg schommelen, is er sprake van een 
hoge glucose variabiliteit. Onze verwachting was dat een daling in de glucose 
variabiliteit een vermindering van het aantal hypo’s zou geven, en daarbij een 
verbetering van IAH. In hoofdstuk 4 hebben we de resultaten beschreven van 
een onderzoek naar het gebruik van een bolus calculator op het verbeteren van 
de glucose variabiliteit bij patiënten met type 1 diabetes en een insulinepomp. 
Deze groep patiënten werd al lange tijd behandeld met een insulinepomp 
en de diabetes was goed ingesteld. Het gebruik van de bolus calculator 
resulteerde desalniettemin in een verbetering van de glucose variabiliteit. Er 
was geen verbetering in de glucose controle, het aantal hypo’s dat voorkwam 
of de kwaliteit van leven. De bolus calculator had daarnaast geen effect op het 
verbeteren van IAH. 
Een hoge glucose variabiliteit kan bijdragen aan het ontstaan en onderhouden 
van IAH. Bij een hoge glucose variabiliteit schommelen de glucosewaarden erg. 
Indien sprake is van een hoge glucosewaarde wordt dit vaak gecorrigeerd met 
teveel insuline. Hierdoor daalt de glucosewaarde te snel en ontstaat een hypo. 
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Veel hypo’s leiden weer tot het ontstaan van IAH. Een verbetering in de glucose 
variabiliteit zou dus kunnen leiden tot een verbetering in IAH. Sodium glucose 
cotransporter 2 (SGLT-2) remmers en glucagon-like-peptide 1 (GLP-1) 
receptor agonisten hebben in eerder onderzoek een verbetering van de glucose 
controle laten zien zonder toename van het aantal hypo’s. Beiden worden 
momenteel gebruikt in de behandeling van patiënten met type 2 diabetes. Het 
werkingsmechanisme verschilt, maar beide medicijngroepen zorgen voor een 
verbetering van de glucose variabiliteit door het verlagen van de glucosepiek 
na de maaltijden. Uit eerder onderzoek is dit ook effectief gebleken bij patiënten 
met type 1 diabetes. We hebben daarom twee studies verricht naar het 
effect van zowel een SGLT-2 remmer als een GLP-1 receptor agonist op 
verbeteren van IAH bij patiënten met type 1 diabetes. De patiënten ondergingen 
in deze studies een glucose clamp, hierbij werd in een experimentele opzet de 
glucosewaarde in het bloed verlaagd tot een hypo. Dit gebeurde met behulp van 
een insuline en een glucose infuus. Tijdens de clamp werden op verschillende 
momenten bloedwaarden bepaald en vragenlijsten over symptomen van 
een hypo afgenomen. In hoofdstuk 5 beschreven we het effect van 6 weken 
behandeling met exenatide (GLP-1 receptor agonist) op IAH. Exenatide zorgde 
voor een daling in het gewicht en BMI. Er was echter geen effect op glucose 
variabiliteit of het aantal hypo’s. Daarnaast trad geen verbetering op van 
IAH. In hoofdstuk 6 beschreven we het effect van 8 weken behandeling met 
dapagliflozine (SGLT-2 remmer) op IAH. Dapagliflozine zorgde voor een 
daling in de glucose variabiliteit en een verbetering van de glucose controle 
(HbA1c waarde) zonder een toename van het aantal hypo’s. Er trad echter geen 
verbetering van IAH op. 
Conclusie 
Impaired awareness of hypoglycemia en ernstige hypo’s blijven een veel-
voorkomend probleem bij patiënten met diabetes ondanks verbeteringen in 
de diabetes zorg. De prevalentie van IAH bij type 1 diabetes is rond de 25-30%. 
Onderzoek in deze thesis liet zien dat IAH ook voorkomt bij ongeveer 10% 
van de patiënten met type 2 diabetes die insuline gebruiken. IAH ontstaat als 
gevolg van gewenning aan hypo’s. Het precieze onderliggende mechanisme is 
niet volledig bekend, in een van onze onderzoeken lieten we zien dat lactaat 
en de bloeddoorstroming in de hersenen hier mogelijk een rol in spelen. 
Lactaat kan mogelijk als alternatieve brandstof gebruikt kan worden wanneer 
glucosewaarden in het bloed laag zijn. Lactaat zorgde daarnaast voor een 
toename in de bloeddoorstroming van de hersenen tijdens hypo, waardoor 




worden. IAH is een proces dat omgekeerd kan worden door het strict 
vermijden van hypo’s voor een aantal weken. Daarnaast speelt een hoge 
glucose variabiliteit een rol bij het ontstaan en onderhouden van IAH. 
We onderzochten in deze thesis 3 mogelijke methoden om de glucose 
variabiliteit te verlagen, het aantal hypo’s te verminderen en daardoor IAH 
om te keren. Het gebruik van een bolus calculator liet verbetering van de 
glucose variabiliteit zien, echter er was geen verschil in het aantal hypo’s en 
geen verbetering van IAH. Mogelijk dat de patiënten in onze studie al veel 
ervaring hadden in het gebruik van de insulinepomp en daardoor minder 
profijt van de bolus calculator hadden. Het gebruik van de bolus calculator 
zou bijvoorbeeld van toegevoegde waarde kunnen zijn bij patiënten die net 
met een insulinepomp starten. Daarnaast hebben we in deze thesis laten 
zien dat het gebruik van exenatide geen effect had op de glucose variabiliteit 
en op IAH. Dapagliflozine zorgde daarentegen voor een verlaging van 
de glucose variabiliteit en verbetering van het HbA1c. Er was echter geen 
verbetering van IAH in deze studie. IAH blijft hiermee een veelvoorkomend 
probleem en vooralsnog lastig om te keren in patiënten met type 1 diabetes. 
Toekomstig onderzoek blijft nodig om de ziektelast van patiënten met IAH te 
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form of Case Report Forms. All studies described in this thesis were conducted 
according to the principles of the declaration of Helsinki and were approved by 
the Medical Ethics Committee of the Radboudumc. All study participants gave 
written informed consent before participation. Data generated in this thesis are 
part of published articles and files are available upon reasonable request. 
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niet tot stand gekomen! Ik heb bewondering voor de inzet die jullie geven voor 
deelname aan de onderzoeken en het enthousiasme om hier beide iets van te 
leren. Ik besef me dat de (bijna) wekelijkse telefoontjes en voorbereidingen 
veel tijd kostten, laat staan de uren die jullie in het ziekenhuis/research centrum 
hebben doorgebracht (met én zonder hypoglykemie). Ik vond het prettig om 
jullie beter te leren kennen en om jullie ervaringen met diabetes te horen en 
hiervan te leren. Ik hoop dat er in de toekomst nog vele onderzoeken verricht 
worden en dat de ontwikkelingen op het gebied van diabetes elkaar snel 
opvolgen. 
Prof. dr. de Galan, beste Bastiaan, ik weet nog goed dat ik bij jou en Cees op 
sollicitatiegesprek kwam. Jullie waren oprecht verbaasd dat er nog iemand 
op de officiële vacaturewebsite van het Radboudumc keek. Tijdens ons eerste 
gesprek wist ik nog niet zo goed wat me te wachten zou staan, maar hier kwam 
snel verandering in. Jouw begeleiding in dit hele traject heb ik als erg prettig 
ervaren. Ik kon altijd bij je terecht voor vragen en advies. Ik heb bewondering 
voor je aanstekelijke enthousiasme en de manier waarop je resultaten toch altijd 
op een positieve manier kunt interpreteren, ook al zijn ze misschien niet zoals je 
in eerste instantie verwacht had. Ik heb heel veel van je geleerd, van je manier 
van schrijven tot aan het verrichten van hypoglykemische clamps. Bedankt voor 
je fijne samenwerking, je eerlijkheid en het vertrouwen dat je me hebt gegeven! 
Prof. dr. Tack, beste Cees, als beginnende PhD-student heb ik veel aan jouw 
adviezen en begeleiding gehad. Ik kon altijd bij je terecht om te sparren over 
resultaten of om de hoofdlijnen van het proefschrift weer even op een rijtje te 
zetten. Daarnaast konden we wekelijks genieten van je Nederlandse of Duitse 
spreekwoorden en stellingen tijdens onze meetings. Ik heb bewondering voor 
de manier waarop je onderzoek, onderwijs, kliniek en je vrije tijd combineert, 
ik geloof niet dat ik dat voor elkaar zou krijgen. Jij wist altijd de puntjes op de 




van een artikel. Ik wil je bedanken voor je enthousiasme, je vertrouwen en je 
eerlijkheid. Ik heb erg veel van jou en Bastiaan geleerd! 
Leden van de manuscriptcommissie, Prof. dr. Vermeulen, Prof. dr. de Wildt, Prof. 
dr. Brouwers, dank voor het lezen en kritisch beoordelen van mijn manuscript. 
Mijn dank gaat ook uit naar de collega’s van het Radboudumc Technology Center 
Clinical Studies. Karin, Eveline, Eline, Anja, Adrianne, Sanne, Jordi, bedankt 
voor jullie hulp bij de vele onderzoeksdagen! Als ik een klein paniek momentje 
had met een kapotte infuuslijn of tekort aan insuline/glucose, dan waren jullie 
snel in de buurt om te helpen. Hopelijk is de spierpijn in jullie armen en rug weer 
een beetje bijgetrokken na de MRI studie. Altijd gezellig om even met jullie bij 
te kletsen, gelukkig kregen we daar tijdens de clamps genoeg tijd voor. Wellicht 
zien we elkaar nog eens in de toekomst!
Dan wil ik ook graag collega’s van de afdeling Radiologie bedanken. Arend en 
Marinette, bedankt voor jullie samenwerking en kritische en waardevolle blik 
op het lactaat paper! Evita, ik vond het erg leuk om deze studie samen met jou 
op te starten en daarmee een vervolg aan de eerdere studies van jou en Hanne 
te geven. Ik heb veel geleerd van al jouw technische kennis. Hopelijk spreken 
we elkaar nog eens in de toekomst! 
Sjaak, wat waren de onderzoeksochtenden gezellig met jou! Ik kan me geen 
dag herinneren dat je niet met een grote glimlach op je gezicht binnen kwam. 
Jouw opgewektheid werkt aanstekelijk en had ook altijd een positief effect op 
de studiedeelnemers. Af en toe werden we zelfs verrast met een zonnige Hawaii 
blouse. Ik zal de koffie momentjes (met wat lekkers uiteraard) gaan missen, net 
als de leuke verhalen over je gezin en uiteraard al je muzikale kennis en feitjes. 
Bedankt voor je eindeloze geduld om dingen uit te leggen, je hulp tijdens de 
onderzoeksochtenden en je openhartigheid! 
Daarnaast wil ik alle coauteurs van de verschillende papers bedanken voor 
hun kritische blik en fijne samenwerking. Graag wil ik ook de internisten/
diabetologen van het Radboudumc bedanken voor hun hulp bij het werven van 
studiedeelnemers en de adviezen en feedback op presentaties tijdens het MDO 
op maandag. Daarnaast dank ik ook de diabetesverpleegkundigen, Sandra van 
den Heuvel en Lisa, voor jullie samenwerking tijdens de bolus calculator studie, 
en jullie hulp bij de voorbereidingen voor alle andere studies. Sandra Hendriks, 
bedankt voor je hulp bij alle bestellingen en uitleg over de sensoren die we 
tijdens de studies gebruikt hebben.
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Dan wil ik ook mijn voorganger, en degene die me geïntroduceerd heeft in de 
wereld van onderzoek doen, bedanken. Hanne, ik weet nog goed dat ik me een 
beetje verloren voelde die eerste dag in de Buitenhoek. Maar jij maakte dit al 
snel veel beter. Ik heb veel van je geleerd, van praktische/administratieve zaken 
voor je onderzoek regelen, tot natuurlijk het uitvoeren van de hypoglykemische 
clamps. Bedankt voor de gezelligheid tijdens het werk, maar zeker ook in de 
periode daarna. Veel succes in de toekomst! 
Ook de overige collega’s binnen het diabetes onderzoeksteam wil ik natuurlijk 
graag bedanken. Anouk, wat ben jij een bikkel zeg. Hoe anders begonnen allebei 
onze PhD-trajecten. Ik heb echt bewondering voor hoe jij je hier doorheen hebt 
geslagen! Ik vond het erg gezellig om met je samen te werken, naar borrels/
etentjes te gaan en samen op congres als 2 PhD-groentjes. Ik ben blij met jou 
als paranimf aan mijn zijde! Hopelijk gaan we elkaar in de toekomst nog vaak 
zien. Clementine, ik vond het leuk om het clampen aan jou door te geven. 
Ik bewonder de manier waarop je je studie hebt opgezet en vol energie bent 
begonnen en het inmiddels ook hebt afgemaakt. Veel succes nog met de laatste 
loodjes! Julia, als jij binnenkomt is meteen iedereen vrolijk. Je positieve energie 
werkt aanstekelijk. Ik vond het heel gezellig om deels samen met jou aan onze 
studie te werken, en ik ben je dankbaar voor de uren die je daardoor extra in 
het lab hebt doorgebracht. Heel veel succes verder met je studies! Namam en 
Linda, ook jullie wil ik bedanken voor de gezelligheid en veel succes wensen in 
de toekomst! 
Dan natuurlijk Jelmer, mijn roomie. Je hebt me denk ik op goede maar ook 
mindere dagen gezien, maar wist me altijd op te vrolijken! Ik heb veel van je 
geleerd op wetenschappelijk, maar vooral ook niet-wetenschappelijk gebied. 
Door jou was ik altijd op de hoogte van de laatste video’s/liedjes/gifjes. Ik 
vond de dagen op onze kantoren (eerst in de Buitenhoek en later op de nieuwe 
afdeling) altijd gezellig. Ik ga de vrijdagmiddag muziekuurtjes wel missen. Ik 
wens je heel veel succes in de toekomst!
Ook de overige AIG collega’s wil ik graag bedanken. Rinke, Jacqueline, Kathrin, 
Xanthe en Steef, ook met jullie heb ik een hele leuke tijd gehad. Bedankt voor 
de gezelligheid op de dansvloer bij de ADDRM, tijdens de jaarlijkse diabetes 
BBQ en op de werkvloer! Vera en Valerie, bedankt dat ik mijn laatste weken/
maanden op jullie kantoor heb mogen bivakkeren. Ik vond het gezellig om 
met jullie bij te kletsen en ervaringen (en struggles) samen te kunnen delen! 
Anneke, bedankt voor je hulp bij onze studies! Overige collega’s van het lab 
AIG; Charlotte, Julia, Martin, Rob, Nico, Harsh, Leonie, Siroon, Inge, Simone, 
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Maartje, Marlies, Jessica, Viola, Rutger, Laszlo, Kathrin, Jorge, Anna, Mariolina, 
Diletta, Intan, Michelle, Daniela, Freek, Ruiqi, Vicky, Rosalie, Fadel, Cor, Helga. 
Ik was toch een beetje een buitenbeentje dat niet echt op het lab kwam, maar 
dat was geen enkel probleem. Ik vond het gezellig om samen te lunchen, koffie 
te drinken of te borrelen! 
Collega’s uit het Maxima MC, bedankt voor het warme welkom dat jullie me 
gaven. Bedankt voor jullie steun en begrip, en voor het af en toe aanhoren van 
mijn frustraties. Ik ben blij met jullie als collega’s en hoop dat we samen nog een 
leuke tijd gaan hebben. Ik kijk er naar uit om de komende jaren met jullie samen 
te werken. 
Mijn leven als student begon in Maastricht, bij de start van de bachelor 
Gezondheidswetenschappen. Susan, Loes, Britt en Rian, ik ben blij dat ik jullie 
toen ben tegengekomen. Als onvervalste trein Limbo’s hebben we uren samen 
doorgebracht. Van samen werken aan groepsopdrachten, tot zwoegen voor 
het SPSS tentamen, we hebben denk ik lief en leed gedeeld. Bedankt voor 
jullie vriendschap, ik vind het mooi om te zien hoe we samen zijn begonnen, 
en toch allemaal een eigen weg hebben bewandeld. Ik hoop jullie nog veel te 
spreken in de toekomst! Naget en Lisa, mijn Geneeskunde buddies, ook jullie 
wil ik bedanken voor de jaren die we samen in Maastricht hebben doorgebracht, 
van samen studeren voor de stationstoets tot eten bij onze favoriete Sushi 
restaurants. Veel succes in de toekomst en hopelijk tot snel! 
Manon, Femke, Michelle en Anne, ik zou niet weten wat ik zou moeten zonder 
jullie gezelligheid, stapavonden, weekendjes weg en vakanties! We kennen 
elkaar al heel lang, maar met jullie is het nooit saai. Ik ben blij dat ik het analyseren 
van studieresultaten kon afwisselen met het oefenen van de nieuwste 
carnavalsliedjes en het uitdenken van onze nieuwste carnavalsoutfit. Bedankt 
dat jullie er altijd voor me zijn, voor jullie adviezen, afleiding en gezelligheid! 
Bende van ellende, Manon, Mireille, Teuntje en Jana, ook zonder jullie zou 
mijn leven er een stuk saaier uitzien. Bedankt voor jullie steun en adviezen de 
afgelopen periode. Ik heb genoten van alle leuke, gekke en gezellige momenten 
die we samen al hebben meegemaakt, en ik hoop dat we er nog heel veel mogen 
maken in de toekomst! Sasha, Kim, Marike, jullie ook bedankt voor de leuke tijd 
als volleybal buddies en het afschakelen van werk hierdoor. Gwen en Marlou, 
door jullie blijf ik altijd een beetje verbonden met Nijmegen. Ook jullie ken ik al 
heel lang, maar als we elkaar zien is het altijd als vanouds. Ik ben heel dankbaar 
voor onze vriendschap en het feit dat ik bij jullie altijd mezelf kan zijn. Bedankt 




Robert-Paul, na mijn familie ben jij denk ik degene die het meest betrokken is 
geweest bij deze hele periode. Bedankt voor het aanhoren van alle onzeker-
heden, frustraties en gelukkig ook vele mooie ervaringen. Ik waardeer je 
eerlijkheid en vertrouwen. Als ik weer eens euforisch was na publicatie van 
een van mijn onderzoeken, dan was jij daar om me weer met twee benen op 
de grond te zetten door te vragen ‘Maar heb je nu ook iets baanbrekends 
onderzocht?’. Bedankt voor het ontwerpen van de prachtige kaft van dit 
proefschrift en je creatieve input. Ik ben je heel dankbaar voor onze waarde-
volle vriendschap en je steun de afgelopen jaren! 
Familie, opa en oma, ooms en tantes, neven en nichten, bedankt voor jullie 
interesse en steun tijdens deze afgelopen jaren! 
Elles en Nikki, lieve zusjes, ook jullie wil ik uiteraard bedanken. Als er twee 
mensen zijn die me door en door kennen dan zijn jullie het wel. Ik denk dat jullie 
minstens zoveel, maar waarschijnlijk nog meer stress hebben ervaren tijdens 
deze afgelopen jaren, wanneer ik net op tijd (of in jullie ogen eigenlijk veel te laat) 
bezig was met voorbereidingen voor onderwijs of een presentatie. Ik bewonder 
jullie discipline en doorzettingsvermogen in alles wat jullie doen en ben trots 
op wat jullie allemaal bereikt hebben! Bedankt voor jullie onvoorwaardelijke 
liefde en steun, en jullie waardevolle adviezen! Dion en Koen, ook jullie wil ik 
bedanken voor jullie interesse, steun en adviezen, en natuurlijk een gezellig 
biertje op zijn tijd. Jullie zijn inmiddels als familie! 
Tenslotte, papa en mama, ik weet eigenlijk niet zo goed waar ik moet beginnen. 
Ik kan me geen moment herinneren dat jullie me niet gesteund, gemotiveerd 
of achter me gestaan hebben. Jullie hebben een basis gelegd en dat is een 
super uitgangspunt voor de rest van mijn leven. Bedankt voor de wijze lessen 
en alles wat jullie ons geleerd hebben. Bedankt ook voor jullie interesse in alles 
wat ik doe, jullie adviezen en steun, en voor de ontelbare mooie herinneringen 
die we samen hebben gemaakt tot nu toe. Mama, met jou kan ik altijd sparren 
over medische vragen en weet dan zeker dat je een goed advies zal geven. Ik 
bewonder je enthousiasme voor je werk en hoe je je hard maakt voor de mensen 
voor wie je zorgt. Ik hoop dat ik hierin op jou lijk. Papa, wat ben ik trots op jou en 
op alles wat je bereikt hebt in je leven. Je kennis, eerlijkheid, oprechtheid en de 
manier waarop je eigenlijk met bijna iedereen wel goed kon opschieten. Ik kan 
nog veel leren van jouw doorzettingsvermogen! Wat had ik graag gehad dat je 
dit mee had kunnen maken. Bedankt voor jullie onvoorwaardelijke liefde, jullie 
zijn twee fantastische voorbeelden voor mij! 
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Dankwoord
